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1. INTRODUCTION 
1.1 Oral Drug delivery System
 
Sastry SV et al, 2000 A drug may be defined as an agent, intended for use in 
the diagnosis, mitigation, treatment cure or prevention of disease in man or in 
animals. Drugs are very rarely administered in the original pure state. They are 
converted into suitable formulation which is converted into suitable formulation 
which is called dosage forms. Every dosage form is a combination of the drug and 
other non drug components. The non drug components are known as additives are 
used to give a particular shape to the formulation to increase its stability and also to 
increase its palatability as well as to give more elegance to preparation. 
1.2 Various pharmaceutical dosage forms  
Dosage forms can be classified based on different route of administrations or 
based on the physical state 
Route of administration Dosage forms 
Oral Powders, Tablets, Capsules, Solutions, 
Emulsions, Syrups, Elixir, Magmas, 
Gels, Catchets, Pill. 
Parentral Sol tions, Suspensions, Emulsions 
Transdermal Ointments, Creams, Powder, Pastes, 
Lotions, Plaster Rectal Suppositories, Tablets, Ointments, 
Creams, Douches, Foams  Urethral Suppo itories 
Sublingual Lozenges, Tablets 
Intranasal Solutions, Sprays, Inhalations. 
Conjuctival Ointments 
Intra-occular Solutions 
Intra-respiratory Aerosols 
Table 1. Various route of administrations and respective dosage forms 
Tablets 
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Tablets are solid dosage form each containing a unit dose of one or more 
medicaments. They are intended for oral administration. A tablet consists of active 
medicament along with excipients which are in powder form are compressed or 
pressed into solid dosage form. 
1.3 Various types of tablets 
1.3.1 Oral Tablets for Ingestion: 
1. Compressed tablets 
2. Multiple compressed tablets 
3. Layered tablets 
4. Compression-coated tablets 
5. Repeat-action tablets 
6. Delayed-action and enteric-coated tablets 
7. Sugar and chocolate-coated tablets 
8. Film coated tablets 
9. Chewable tablets 
1.3.2 Tablets Used in the Oral Cavity: 
1. Buccal tablets 
2. Sublingual tablets 
3. Troches and lozenges 
4. Dental cones 
1.3.3 Tablets Administered by Other Routes: 
1. Implantation tablets 
2. Vaginal tablets 
1.3.4 Tablets Used to Prepare Solutions: 
1. Effervescent tablets 
2. Dispensing tablets 
3. Hypodermic tablets 
      4. Tablet triturates 
1.4 Orally Disintegrating Tablets 
Oral administration is the most popular route due to ease of ingestion, pain 
avoidance, versatility (To accommodate various types of drug candidates) and most 
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importantly, patient compliance. Also, solid oral delivery systems do not require 
sterile conditions and are, therefore, less expensive to manufacture. A vast variety of 
pharmaceutical research is directed at developing new dosage forms for oral 
administration. Most of these efforts have focused on either formulating novel drug 
delivery systems or increasing the patient compliance. Among the dosage forms 
developed for facilitating ease of medication, the orally disintegrating systems have 
been the favourite of product development scientists. In similar fashion the oral 
cavity is highly acceptable by patients, the mucosa is relatively permeable with rich 
blood supply and virtual lack of langerhans cells makes oral mucosa tolerant to 
potential allergens. 
1.5 Overview of Oral Mucosa 
The oral cavity comprises Journal the lips, cheek, tongue, hard palate, soft 
palate and floor of the mouth (Fig. 1). The lining of the oral cavity is referred to as 
the oral mucosa, and includes the buccal, sublingual, gingival, palatal and labial 
mucosa. The buccal, sublingual and mucosal tissues at the ventral surface of the 
tongue account for about 60% of the oral mucosal surface area. The top quarter to 
one-third of the oral mucosa is made up of closely compacted epithelial cells. 
The primary function of the oral epithelium is to protect the underlying tissue 
against potential harmful agents in the oral environment and from fluid loss. Beneath 
the epithelium are the basement membranes, lamina propia and submucosa. The oral 
mucosa also contains many sensory receptors including the taste receptors of the 
tongue. Three types of oral mucosa can be found in the oral cavity; the lining mucosa 
is found in the outer oral vestibule (the buccal mucosa) and the sublingual region 
(floor of the mouth) (Fig. 1). The specialized mucosa is found on the dorsal surface of 
tongue, while the masticatory mucosa is found on the hard palate (the upper surface 
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of the mouth) and the gingival (gums). 
The lining mucosa comprises approximately 60%, the masticatory mucosa 
approximately 25%, and the specialized mucosa approximately 15% of the total 
surface area of the oral mucosal lining in an adult human. The masticatory mucosa is 
located in the regions particularly susceptible to the stress and strains resulting from 
masticatory activity. The superficial cells of the masticatory mucosa are keratinized, 
and a thick lamina propia tightly binds the mucosa to the underlying periosteum. 
Lining mucosa on the other hand is not nearly as subject to masticatory loads and 
consequently, has a non-keratinized epithelium, which sits on a thin and elastic lamina 
propia and a sub mucosa.(Fig. 2) The mucosa of the dorsum of the tongue is a 
specialized gustatory mucosa, which has well papillated surfaces which are both 
keratinized and some non-keratinized .Depicted the advantages and disadvantages 
associated with utilizing the oral mucosa as a drug delivery site. 
 
 
 
 
 
 
Figure 1: Schematic representation of the different linings of mucosa in mouth. 
1.6 ORALLY DISINTEGRATING DOSAGE FORMS 
The concept of orally disintegrating dosage forms has emerged from the desire 
to provide patients with more conventional means of taking their medication. 
Interestingly, the demand for ODDFs has enormously increased during the last 
decade, particularly for geriatric and paediatric patients who experience difficulty in 
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swallowing conventional tablets and capsules. Hence, they do not comply with 
prescription, which results in high incidence of ineffective therapy  
 
 
 
 
 
 
 
Figure 2: Schematic diagram of buccal mucosa 
Advantages of ODTs (Priyanka Nagar et al, 2011) 
1. ODT can be administer to the patients who cannot swallow tablets/cap, such as the 
elderly, stroke victims, bedridden patients, patients with esophageal problems & 
patients who refuse to swallow such as paediatric, geriatric & psychiatric patients 
and thus improves patient compliance. 
2. It contain the certain studies which concluded increased bioavailability and proved 
rapid absorption of drugs through pregastric absorption of drugs from mouth, 
pharynx & oesophagus as saliva passes down. 
3. ODT is most convenient for disabled, bedridden patients, travellers and busy 
people, who do not always have access to water. 
4. Good mouth feel property of ODT helps to change the perception of medication. 
As bitter pill particularly in paediatric patients.  
5. The risk of chocking or suffocation during oral administration of conventional 
formulations due to physical obstruction is avoided, thus providing improved 
safety.  
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6. ODT opened new business opportunity like product differentiation, product 
promotion, patent extension and life cycle management.  
7. Suitable during travelling where water may not be available.  
8. No specific packaging required can be packaged in push through blisters.  
9. Conventional manufacturing equipment.  
10. Cost effective.  
11. Good chemical stability as conventional oral solid dosage form.  
12. New business opportunity like product differentiation, product promotion, patent 
extension and life style management.  
13. Allow high drug loading.  
14. Provides rapid drug delivery from dosage forms.  
15. Provide advantage of liquid medication in form of solid preparation. 
16. Rapid drug therapy intervention. 
17. No chewing needed. 
19. Adaptable and amenable to existing processing and packaging machinery. 
20. Rapid onset of action. 
Disadvantages of ODTs 
1. ODT is hygroscopic in nature so must be keep in dry place. 
2. Some time it possesses mouth feeling. 
3. It is also shows the fragile, effervescence granules property. 
4. ODT requires special packaging for properly stabilization & safety of stable 
product. 
Formulation aspect of ODT's (JaysukhHirani J et al, 2009) 
Important ingredients that are used in the formulation of ODTs should allow 
quick release of the drug, resulting in faster dissolution. This includes both the 
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pharmacologically active ingredients (drug) and the excipients (additives). 
A. Selection of drug candidate: Several factors may be considered while selecting an 
appropriate drug candidate for development of orally disintegrating tablets. The 
ultimate characteristics of a drug for dissolution in mouth and pregastric absorption 
from fast dissolving tablets include  
1. Free from bitter taste 
2. Dose lower than 20mg 
3. Small to moderate molecular weight  
4. Good solubility in water and saliva  
5. Partially unionized at oral cavity pH 
6. Ability to diffuse and partition in to the epithelium of upper GIT(log >1,or 
preferably>2)  
7. Ability to permeate oral mucosal tissue.  
There are no particular limitations as long as it is a substance which is used as 
a pharmaceutical active ingredient. Researchers have formulated ODT for various 
categories of drugs used for therapy in which rapid peak plasma concentration is 
required to achieve the desired pharmacological response. These include neuroleptics, 
cardiovascular agents, analgesics, anti-allergic, anti-epileptics, anxiolytics, sedatives, 
hypnotics, diuretics, anti-parkinsonism agents, anti-bacterial agents and drugs used for 
erectile dysfunction  
In contrast, the following characteristics may render unsuitable for delivery as 
an orally disintegrating tablet:- 
1. Short half-life and frequent dosing.  
2. Very bitter or otherwise unacceptable taste because taste masking cannot be 
successfully achieved.  
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3. Require controlled or sustained release. 
4. Combination with anticholinergics.  
Techniques in preparation of orally disintegrating drug delivery system 
(RakeshPahwa et al., 2010) 
The various technologies are developed for the preparation ofOrally 
DisintegratingDrugDelivery Systemthat are: 
•  Freeze drying 
•  Spray drying 
•  Molding 
•  Phase transition process 
•  Melt granulation 
•  Sublimation 
•  Mass Extrusion 
•  Cotton Candy Process 
•  Directcompression 
Freeze drying 
Lyophilization means drying at low temperature under condition that involves 
the removal of water by sublimation. Drugging water soluble matrix which is then 
freeze dried to give highly porous structure. The tablets prepared by Lyophilization 
disintegrate rapidly in less than 5 seconds due to quick penetrate on of saliva in pores 
when placed in the oral cavity. Lyophilization is useful for heat sensitive drugs i.e., 
thermo-labile substances. 
Ahmed et al., 2006 prepared lyophilized tablet using freeze drying technique. 
The lyophilized tablet prepared by dispersing drug Ketoprofen in aqueous solution of 
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highly water soluble carrier consisting of gelatin, glycine and sorbitol in blister packs 
and then subjected to Lyophilization in blister packs. It was found that the increase in 
solubility of ketoprofen from lyophilized tablet matrix was nearly three times greater 
than solubility of the plain drug which was duet super saturation generated by 
amorphous form of drug. 
Spray drying 
Spray drying can produce highly porous and fine powders that dissolve 
rapidly. This technique is based on a particulate support matrix, which is prepared by 
spray   drying   an   aqueous   composition   containing support matrix and other 
components to form a highly porous and fine powder. This then mixed with active 
ingredients and compressed into tablets. The formulations are incorporated by 
hydrolyzed and non hydrolyzed gelatine as supporting agents, mannitol as bulking 
agent, sodium starch glycolate or cross carmellose sodium as disintegrating and an 
acidic material (e.g. citric acid) and / or alkali material (e.g. sodium bicarbonate) to 
enhance disintegration and dissolution. Tablet compressed from the spray dried 
powder disintegrated within 20 seconds when immersed in an aqueous medium. 
Allen et al., 2011 used as pray drying technique to prepare fast dissolving 
tablets. Thetabletsmadefromthis technology   are   claimed   to   disintegrate   within   
20 seconds. 
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Direct compression  
This is most popular technique because of its easy implementation and cost-
effectiveness. The basic principle involves addition of disintegrants and/or water 
soluble excipients and/or effervescent agents. Super disintegrates in optimum 
concentration (about2-5%) are mostly used so as to achieve rapid disintegration 
along with the good mouth feel. (RakeshPahwa et al, 2011) 
Bi et al. 1996 examined the disintegrant property of mixture of microcrystalline 
cellulose and low substituted hydroxypropyl cellulose (MCC: L-HPC) for orally 
disintegrating tablet and found that shortest disintegration time was observed in the 
range of ratio of MCC: L-HPC (8:2 to 9:1). 
Gillis et al. prepared a fast-dissolving tablet of Galanth amine hydrobromide which 
comprise of diluent which is a spray dried mixture of lactose monohydrate and micro 
crystalline cellulose in the ratio of 75:25,a cross linked polymeric disintegrant such as 
cros povidone and a direct compression process was used for preparation of fast 
dissolving tablets.  
Gattanietal. Prepared Ondansetron mouth dissolving tablet using treatedagar as a 
super disintegrating agent and found that tablets with treatedagar powder had 
disintegration rate comparable to other super disintegrants. 
Zolmitriptan is an anti-migraine drug. It is widely used for the acute treatment 
of migraines with or without aura.The bioavailability of Zolmitriptan is about 40% 
via oral dosage forms & its problem arises from its low water solubility and 
dissolution rate. Oral Zolmitriptan administration is characterized by slow absorption. 
Zolmitriptan is available in the market as a tablet, conventional dosage form. But this 
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formulation suffers from the bioavailability problem. Among numerous ways of 
enhancing drug dissolution, orally disintegrating tablets are one of the promising 
techniques to overcome the solubility problem of zolmitriptan. The present study is 
focused on the development of zolmitriptan ODT tablets for improved bioavailability. 
Patient counseling points for ODT  
Reddy L. H et al 2002 as pharmacist are ideal person to become familiar with recent 
technology advancement in novel dosage form, thus have opportunity to counsel the patient 
for effective treatment. Educating the patients about ODT can avoid any confusion and 
misunderstanding of this dosage form. 
Counselling points to the patients include: 
· Patients may mistake ODT for effervescent tablets, pharmacist need to be clearly told about 
the different between them. The cima technologies orosolv and durasolv use slight 
effervescence, patients may experience a pleasant tingling effect on the tongue. 
 · ODT need to be handled carefully because some of ODT developed may not have sufficient 
mechanical strength. 
 · Patients with dryness of mouth or with siogrens syndrome or who taking anticholengic 
drugs may not be suitable population for administering ODT.Although no water is needed to 
allow the drug to dispense quickly and efficiently but most technologies of ODT utilizes the 
body own salivation but decreased volume of saliva may slow down dissolution/ 
disintegration/ bioavailability of the product. 
· Although chewable tablets have been in the market for long time, patients need to be 
counseled properly the difference between chewable and ODT tablets.ODT can be used easily 
in children who have lost their primary teeth but do not have full use of their permanent teeth 
and also for geriatric patients who have lost their teeth permanently. 
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 · With the pharmacist counseling, intervention and assistance all of these patients who taking 
ODT could be more properly treated with greater convenience. 
Industrial Applications 
(Kumar et al., 2012, Beri and Sacher, 2013) Industrial applications include the 
following:  
 To develop an orally disintegrating dosage forms and to work with existing 
disintegrants  
 To further improvise upon the existing technology of ODTs  
 To optimize the blend of disintegrants or excipients to achieve ODTs 
 To select and develop proper packaging material and system for enhanced 
stability of the product and also develop a cost-effective product  
 To arrive at various taste-masking agents and prepare palatable dosage forms thereby 
increasing patient compliance 
 To develop disintegrants from different polymers which are used as coating materials 
by certain modifications and use them for formulating ODTs 
Future Prospects 
 These dosage forms may be suitable for the oral delivery of drugs such as 
protein and peptide-based therapeutics that have limited bioavailability when 
administered by conventional tablets. These products usually degrade rapidly in the 
stomach. Should next generation drugs be predominantly protein or peptide based, 
tablets may no longer be the dominant format for dosing such moieties. Injections 
generally are not favoured for use by patients unless facilitated by sophisticated auto-
injectors. Inhalation is one good alternative system to deliver these drugs, but the 
increased research into biopharmaceuticals so far has generated predominantly 
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chemical entities with low molecular weights. 
Challenges and Limitations for ODTs 
 (Velmurugan S, Vinushitha S et al 2010) Drugs with relatively larger doses are 
difficult to formulate into ODTs e.g. antibiotics like ciprofloxacin with adult dose 
tablet containing about 500 mg of the drug. The application for technologies used for 
ODTs is limited by the amount of drug into each unit dose. The drug dose must be 
lower than 400mg for insoluble drugs and 60mg for soluble drugs. However 
Flashdose technology can accommodate larger drug doses and offers improved 
mechanical strength. Orasolv® technology can accommodate a wide range of active 
pharmaceutical ingredient from 1 mg to 500 mg 
• Mechanical strength - ODTs are made of porous or soft molded matrices in order to 
allow its disintegration in mouth. This makes tablet friable and handling becomes 
difficult. Orodispersible tablets with highly porous structure and good mechanical 
strength have been developed by sublimation method. Also Durasolv® has much 
higher mechanical strength than Orasolv due to the use of higher compaction 
pressures during compression. 
• Palatability - ODTs are intended to be dissolved in mouth. Most of the drugs have 
bitter taste. Bitter taste can be masked with enough sweetener and flavors. 
Specifically, methods of taste masking include lipophilic vehicles, coating with 
polymers, carbohydrates, lipids or proteins complexation with cyclodextrins or ion-
exchange resins, formation of salts, use of salting out layers and solid dispersions 
[55]. OraQuick utilizes its own patented taste masking technology i.e. MicroMask®. 
In MicroMask® technology, taste-masking process is done by incorporating drug into 
matrix microsphere. 
• Drugs in form of ODTs are hygroscopic in nature and hence need to be protected 
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from humidity. To overcome humidity problem special working facilities can be 
designed by simple methods and special air-conditioning systems can be set up. Size 
of tablet 7 and 8 mm are easy to swallow while tablets of size 8mm are easy to 
handle. Hence, tablet sizes which are both easy to handle and swallow are difficult to 
achieve. For the patient compliance, to make the swallowing easier, round shape 
punches having optimum dimensions can be used. 
• Drug candidates should be stable both in water and in saliva, should not ionize at 
oral cavity pH and should be able to permeate oral mucosal tissue to diffuse and 
partition in upper GI epithelium (logP > 1, or preferably > 2, not have short half-life). 
To optimize solubility problem of the active pharmaceutical ingredient some solid 
buffers and surfactants can also be chosen. 
Conclusion  
(Aurora J, Pathak V et al 2005) Orally disintegrating tablets have better patient 
acceptance and compliance and may offer improved biopharmaceutical properties, 
improved efficacy, and better safety compared with conventional oral dosage forms. 
Prescription ODT products initially were developed to overcome the difficulty in 
swallowing conventional tablets among pediatric, geriatric, and psychiatric patients 
with dysphagia. Today, ODTs are more widely available as OTC products for the 
treatment of allergies, cold, and flu symptoms. The target population has expanded to 
those who want convenient dosing anywhere, anytime, without water. The potential 
for such dosage forms is promising because of the availability of new technologies 
combined with strong market acceptance and patient demand. By paying close 
attention to advances in technologies, With continued development of new 
pharmaceutical excipients, one can expect the emergence of more novel technologies 
for ODTs in the days to come. 
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2. LITERATURE REVIEW 
2.1 Orally Disintegrating Tablets 
Priyanka Nagar et al., 2011
 
oral delivery which is currently the gold standard in the 
pharmaceutical industry, where it is regarded as the safest, most convenient and most 
economical method of drug delivery having the highest patient compliance. 
Formulation of a convenient dosage form for oral administration, by considering 
swallowing difficulty especially in case of geriatric and paediatric patient leads to 
poor patient compliance. To troubleshoot such problems a new dosage form known as 
orally disintegrating tablet (ODT), has been developed which rapidly disintegrate & 
dissolve in saliva and then easily swallowed without need of water which is a major 
benefit over conventional dosage form. In addition, patients suffering from dysphasia, 
motion sickness, repeated emesis and mental disorders prefer such preparation 
because they cannot swallow large quantity of water. Further, drugs exhibiting 
satisfactory absorption from the oral mucosa or intended for immediate 
pharmacological action can be advantageously formulated in such type of dosage 
form. The popularity and usefulness of the formulation resulted in development of 
several ODT technologies for preparation. The current article is focused on ideal 
characteristics, advantages and disadvantages, formulation aspects, formulation 
technologies, evaluation of products and future potential. Various marketed 
preparations along with numerous scientific advancements made so far in this avenue 
have also been discussed. 
Manoj Ashok Wagh et al., 2010
 
conventional preparation methods are spray drying, 
freeze drying, direct compression, Moulding, and sublimation while new technologies 
have been developed for the production of oro-dispersible tablets. 
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2.2 Various Manufacturing technologies for ODT 
2.2.1 Spray Drying 
Allen L Vetal., 2001 used a spray drying technique to prepare fast dissolving tablets. 
The tablets made from this technology are claimed to disintegrate within 20 seconds, 
which is prepared by spray drying an aqueous composition containing support matrix 
and other components to form a highly porous and fine powder. This then mixed with 
active ingredients and compressed into tablets. 
2.2.2 Flash Tab Technology 
Dinkar Sharma et al., 2012 taste-Masked orally disintegrating tablets of paracetamol 
were prepared by Flash Tab Technology. Taste masked granules of paracetamol were 
prepared by coating the granules of the drug using a pH -sensitive polymer Eudragit 
EPO in a fluidized bed coater and the coated granules were evaluated. Wet 
granulation technique was used for the preparation of the tablets using crospovidone 
and hydroxypropyl cellulose as disintegrants. Disintegration time of the tablets was 
found to be 27 sec and almost 100% drug released in 30 minutes. 
2.2.3 Solid Dispersion Method 
Alshehri SM et al, 2015
 
to enhance the solubility as well as to mask the intensely 
bitter taste of the poorly soluble drug, Mefenamic acid (MA). The taste masking and 
solubility of the drug was improved by using Eudragit
®
 EPO in different ratios via hot 
melt extrusion (HME), solid dispersion technology. Differential scanning calorimetry 
(DSC) studies demonstrated that MA and E PO were completely miscible up to 40% 
drug loads. Powder X-ray diffraction analysis indicated that MA was converted to its 
amorphous phase in all of the formulations. Additionally, FT-IR analysis indicated 
hydrogen bonding between the drug and the carrier up to 25% of drug loading. SEM 
images indicated aggregation of MA at over 30% of drug loading. Based on the FT-
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IR, SEM and dissolution results for the extrudates, two optimized formulations (20% 
and 25% drug loads) were selected to formulate the orallydisintegratingtablets 
(ODTs). ODTs were successfully prepared with excellent friability and rapid 
disintegration time in addition to having the desired taste-masking effect. 
2.2.4 Molding 
Tablets prepared by this method are solid dispersions. Moulded tablets offer improved 
taste due to water- soluble sugars present in dispersion matrix. Different moulding 
techniques can be used to prepare mouth-dissolving tablets: 
a. Compression molding: The manufacturing process involves moistening the 
powder blend with a hydro- alcoholic solvent followed by compressing into mould 
plates to form a wetted mass which is then air dried to remove the solvent. Such 
tablets are less compact than compressed tablets and possess a porous structure that 
has tens dissolution. 
b.Heatmolding: Amolten matrix in which drug is dissolved or dispersed can be 
directly moulded in to oro-dispersible tablets. The tablets prepared using heat 
moulding process involves settling of molten mass that contain a dispersed or 
dissolved drug. In this process, the suspension or solution of drug, a garland sugar is 
prepared and then poured into the blister packaging. The agar solution is then 
solidified at room temperature to form a jelly and dried at 30°C under the vacuum. 
Developed orally disintegrating tablets was found to improve the mouth feel due to the 
presence of the water soluble sugars. 
c.Novacuum lyophilization: This process involves evaporation of solvent from a 
drug solution or suspension at a standard pressure. 
Molded tablets had less mechanical strength. Drug can be present as micro particles 
or discrete particles dispersed in the matrix. However, addingsucrose, acacia or 
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polyvinyl pyrrolidone can increase mechanical strength. They possess highly porous 
structure which is supposed to increase their disintegration and dissolution rates. 
2.2.5 Phase transition process 
The combination of low and high melting point sugar alcohols, as well as a phase 
transition in the manufacturing process, is important form a king orally disintegrating 
tablets without any special apparatus. Here, tablet produced by compressing the 
powder containing two sugar alcohols of high and low melting point and 
subsequently heating at temperature between their two melting points. Orally 
disintegrating tablets were produced by compressing powder containing erythritol 
(melting point: 122°C) and xylitol (melting point: 93-95°C), and then heating at 
about 93°C for 15 min. After heating, the median pore size of the tablets was 
increased and tablet hardness was also increased. The increase of tablet hardness 
with heating and storage did not depend on the crystal state of the lower melting 
point sugar alcohol. 
2.2.6 Melt granulation 
Abdelbary et al., 2014 preparedorally disintegrating tablet by incorporating a 
hydrophilic waxy binder PEG 6- stearate (Superpolystate®) in the formulation. It has 
melting point of 33-37°C and HLB value of 9. It acts as a binder and increases the 
physical resistance of tablet. It helps for fast disintegration of tablet when place in 
mouth and leaving no residue in oral cavity. 
Perissuttietal., 2003developedthe orally disintegrating tablets of Carbamazepine by 
melt granulation technique. The granules were prepared by using poly ethylene 
glycol (PEG-4000) as a melting binder and lactose monohydrate as hydrophilic filler 
without using solvents or water. The dissolution profiles of granules containing 
Crospovidone as an intra-granulating agent were found to be super imposable to 
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those prepared without it. Also, the extra granular addition of a small amount of 
Crospovidone gave rise to a further increase in disintegration rate and dissolution 
performances. 
2.2.7Sublimation 
(Shinde et al., 2010) This technique is based on the use of volatile ingredients (e.g. 
camphor, ammonium bicarbonate, naphthalene, urea, urethane, etc.) to other tablet 
excipients and the mixture is then compressed into tablets. Entrapped volatile material 
is then removed via sublimation, which leads to formation of a porous structure. These 
compressed tablets which have high porosity (approximately30%) rapidly dissolved 
within 15seconds in saliva. Several solvents like cyclohexane, benzene etc. can also be 
used as pore forming agents. Orodispersible tablets with highly porous structure and 
good mechanical strength have been developed by this method. 
Koizumi et al, 1997 prepared highly porous compressed tablets. They used mannitol 
as a tablet matrix material while camphor as subliming agent. Camphor was removed 
by subliming in vacuum at 80°C for 30 minutes to develop pores in the tablets. 
Makino et al., 1998 described a method of producing a fast dissolving tablet using 
water as a pore forming material. They used a mixture containing active ingredient 
and carbohydrates (glucose, mannitol, xylitol etc.) which then moistened with water 
(1-3%w/w) and compressed into tablets. Then water was removed, yielding highly 
porous tablet. 
2.2.8 Mass Extrusion 
In this technique, a blend of active drug and other ingredients is softened using 
solvent mixture of water soluble polyethylene glycol, using methanol and then 
softened mass is extruded through the extruder or syringe to get a cylinder of product, 
which is finally cut into even segments with the help of heated blades to get tablets. 
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The dried cylinder can be used to coat the granules of bitter tasting drugs and thereby 
masked their bitter taste. 
2.2.9 Cotton Candy Process 
This process utilizes unique spinning mechanism to produce floss-like 
crystalline structure. Cotton candy process involves formation of matrix of 
polysaccharides or saccharides by simultaneous action of flash melting and spinning. 
The matrix formed is partially recrystallized to improve flow property and 
compressibility. This candy floss matrix is then milled and blended with active 
ingredients and excipients and subsequently compressed to orally disintegrating 
tablet. This process can accommodate larger drug doses and offers improved 
mechanical strength. However, high- process temperature limits the use ofthis 
process. 
2.2.10 Direct Compression: 
(Battu s ket al, 2007) formulation of directly compressible rapidly disintegrating 
tablets of fenoverine with sufficient mechanical integrity, content uniformity, and 
acceptable palatability to assist patients of any age group for easy administration was 
carried out. Effect of varying concentrations of different superdisintegrants such as 
crospovidone, croscarmellose sodium, and sodium starch glycolate on disintegration 
time was studied. In which crospovidone shows superior disintegration in the 
formulation.  
Farshid A et al, 2014 Zolmitriptan tablets were prepared by direct compression 
method and sublimation method by using Menthol and Camphor as subliming agent 
and their pre and post compression parameters were determined. The dissolution 
studies were performed at 37°C±5°C and at 50 rpm in pH 6.8 phosphate buffer. In this 
study formulation with insoluble diluents and disintegrants were found to be better 
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than tablets containing soluble diluents and disintegrants. By sublimation method, 
menthol was found better than camphor in disintegration and drug release 
HazeePeera N et al, 2013 orally disintegrating tablets of Zolmitriptan prepared by 
direct compression and using Supertab11SD, Avicel PH 102, Crospovidone, Ac-Di-
Sol, Sodium starch glycolate, Aspartame, Magnesium stearate were prepared and 
evaluated for the pre compression parameters such as bulk density, compressibility, 
angle of repose etc. The prepared batches of tablets were evaluated for hardness, 
weight variation, friability, disintegration time and in-vitro dissolution profile and 
found satisfactory. Among the three groups, F9 Formulation as the best formulation 
and showed maximum dissolution rate with drug release. 
El-Setouhy DA et al, 2015
 
formulation of sublingual tablets of Zolmitriptan using 
novel surfactant binder with limited permeability poses a great challenge due to their 
poor absorption. In this study, bioenhanced sublingual tablets (BESTs) of zolmitriptan 
were prepared using novel surfactant binder (Pluronic® p123/Syloid® mixture) to 
enhance tablet disintegration and dissolution. Microencapsulated polysorbate 80 
(Sepitrap™ 80) were included in the composition of BESTs to enhance the drug 
transport through the sublingual mucosa. Tablets were evaluated for in vitro/in vivo 
disintegration, in vitro dissolution and ex vivo permeation. Solubility studies 
confirmed that phosphate buffer; pH 6.8 could be used as dissolution medium for 
sublingual tablets of zolmitriptan. BEST-5 containing Pluronic® p123/Syloid® 
mixture and Sepitrap™ 80 exhibited the shortest in vitro/in vivo disintegration times 
(<30s), the highest dissolution at early time dissolution points and the highest 
enhancement of drug transport through mucosal membrane. The in vivo 
pharmacokinetic study using human volunteers showed a significant increase in the 
rate and extent of sublingual absorption with less variations of Tmax after sublingual 
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administration of both BEST-5 and Zomig-ZMT ODT. Our results proposed that 
Pluronic® p123/Syloid® mixture and Sepitrap™ 80 could be promising for the 
development of sublingual tablets for rapid onset of action of drugs with limited 
permeability.  
(Ademir Barianni Rodero et al, 2009) in most of the ODT formulation of 
Zolmitriptan, Asparatame is used as sweetener. Considering the side effects of 
Asparatame, sucralose can be considered as the sweetener which shows equal 
potential. Sucralose is a non-nutritive artificial sweetener, 600 times sweeter than 
sucrose, and is very stable at high temperatures, among other characteristics. 
2.3 Various drug delivery systems used in Zolmitriptan formulation 
2.3.1 Combinational therapy using Triptans and NSAID. 
(Kumar A et al., 2015) combinational formulation of Triptans and NSAID may 
provide a quicker and longer duration of relief from the subsequent pain during the 
attack. In this study, formulation of Zolmitriptan (ZT) & ketorolac tromethamine 
(KT) loaded thermo reversible in-situ mucoadhesive intranasal gel (TMISG) 
formulation which gels at the nasal mucosal temperature and contains a bioadhesive 
polymer (Xyloglucan) that lengthens the residence time will enhance the 
bioavailability of the combinational drugs. This study uses Box-Behnken design for 
the first time to develop, optimize the TMISG and assess factors affecting the critical 
quality attributes. Histopathological study of the nasal mucosa suggested that the 
formulation was safe for nasal administration. The statistical difference in absolute 
bioavailability between oral and intranasal route suggested that intranasal route had 
almost 21% increases in bioavailability for ZT and for KT there was 16% increase 
over oral formulations. Optimized formulation would help mitigate migraine 
associated symptoms much better over the currently available formulations. 
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Subedi RK et al., 2011 the effects of different formulation variables including 
pressure sensitive adhesive (PSA), thickness of the matrix, solvent system, inclusion 
of crystallization inhibitor, loading amount of drug and enhancers on the transdermal 
absorption of zolmitriptan were investigated. Acrylic adhesive with hydroxyl 
functional group provided good adhesion force and high flux of zolmitriptan. 
Pseudopolymorphs of zolmitriptan were found to possess different solid-state 
properties that affected the permeation rate. Polyoxyethylene alkyl ethers significantly 
increased the permeation of zolmitriptan through hairless mouse skin. However, these 
enhancers induced crystallization of zolmitriptan. Kollidon(®) 30 delayed the 
crystallization without altering the permeation profile of zolmitriptan. Stability studies 
suggested that terpenes did not induce crystallization of zolmitriptan in the patch and 
stable formulations could be produced by using cineole and limonene, or their 
combination. 
Subedi RK et al., 2011 transdermal patch for Zolmitriptan have determined it’sin 
vivo absorption using the rabbit skin. Solvent evaporation technique prepared 
zolmitriptan patch was settled in two-chamber diffusion cell combined with excised 
rabbit abdomen skin for permeation study. A sufficient cumulative penetration 
amount of Zolmitriptan (258.5 ± 26.9 μg/cm2 in 24 h) was achieved by the 
formulation of 4% Zolmitriptan, 10% Azone, and adhesive of DURO-TAK® 87-
4098. Pharmacokinetic parameters were determined via I.V and transdermal 
administrations using animal model of rabbit. The results revealed that the absolute 
bioavailability was about 63%. Zolmitriptan could be detected with drug level of 
88 ± 51 mg/mL after transdermal administration of 15 min. The in vivo absorption 
curve obtained by de convolution approach using WinNonlin® program was 
correlated well with the in vitro permeation curve, the correlation coefficient R is 
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0.84, and the result indicated that in vitro skin permeation experiments were useful to 
predict the in vivo performance. In addition, little skin irritation was found in the 
irritation study. As a conclusion, the optimized zolmitriptan transdermal patches could 
effectively deliver adequate drug into systemic circulation in short time without 
producing any irritation phenomenon and worth to be developed. 
 The present study is aimed to develop a optimized ODT of Zolmitriptan 5mg 
by simple manufacturing process and with reduced number of excipients.  
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3. AIM &OBJECTIVE 
Difficulty in swallowing (dysphagia) is a common problem of all age 
groups, especially the elderly and pediatrics, because of physiological changes 
associated with those groups. Other categories that experience problems in 
using conventional oral dosage forms include the mentally ill, uncooperative 
and patients suffering from nausea, motion sickness, sudden episodes of allergic 
attack or coughing. Sometimes it may be difficult to swallow conventional 
products due to non-availability of water. These problems led to the 
development of a novel type of solid oral dosage form called orodispersible 
tablet, which disintegrates/dissolves rapidly in saliva without the need of 
drinking water. 
The benefits in terms of patient compliance, rapid onset of action, 
increased bioavailability and good stability make these tablets popular as a 
dosage form of choice in the current market. Some drugs are in such cases 
bioavailability of drug is significantly greater than those observed from 
conventional tablet dosage form. 
The basic approach used in the development of the ODTs is the use of 
superdisintegrants. Many approaches have been developed to manufacture 
ODTs. These include vacuum drying direct compression, lyophilization and 
molding. The direct compression method is inexpensive and convenient for 
producing tablets of sufficient mechanical strength. 
Zolmitriptan are the new serotogenic agonist with excellent oral 
bioavailability exhibiting a potent symptomatic antimigraine effect. 
Zolmitriptan is a selectiveagonist of 5-HT1 B/D receptors. 
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In the present study, orodispersible tablets of Zolmitriptan are 
designed by using polymers namely Pharmabusrst, Pearlitol Flash and 
Panexcea ODT. Effervescent substances like citric acid and sodium stearyl 
fumarate. 
Accelerated the superdisintegrant action and mask the bitter taste of 
zolmitriptan. The designed tablets were evaluated for thickness, hardness, 
friability, weight variation, in vitro dispersion time, wetting time, water 
absorption ratio, disintegration time, drug content uniformity, in vitro 
dissolution rate (in pH 6.8 phosphate buffer), short term stability and drug 
excipient interactions (IR spectroscopy). 
OBJECTIVES OF THE WORK: 
The present work is an attempt: 
   
1. To formulate and evaluate orodispersible tablets. 
2. To enhance the bioavailibity. 
3. Ease of administration to paediatrics and geriatrics.  
4. To evaluate for the pre-formulation characteristics of powder mixture like bulk 
density, flow property, angle of repose, compressibility index etc. 
5. To evaluate the post-formulation characteristics of the tablet like hardness, 
friability, disintegration time, dispersion time, etc. 
6. To carry out in vitro dissolution studies of the tablet formulations. 
7. To carry out stability studies according to ICH guidelines 
To formulate orally disintegrating tablets of Zolmitriptan, 5 mg by a simple 
direct compression process and to evaluate the physico-chemical characteristics of the 
designed tablets against the marketed product.  
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4. PLAN OF WORK 
 
 Literature survey 
 Procurement of raw materials and drug (zolmitriptan) 
 Preformulation studies of zolmitriptan 
 Characterization of zolmitriptan 
 Preparation of zolmitriptan - ethylcellulose mixture (Taste masking) 
 Pre-compression evaluation 
 Compression of final blend into tablets 
 Post-compression evaluation 
 In-vitro drug release studies 
 Comparison of optimized formulation and marketed ODT preparation 
 Stability studies 
 Drug release kinetics 
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5. DRUG & EXCIPIENT PROFILE 
5.1 ZOLMTIPTAN 
Chemical Structure 
 
IUPAC Name  :(S)-4-({3-[2-(dimethylamino)ethyl]-1H-indol-5-
yl}methyl)-1,3-oxazolidin-2-one 
Description   : Zolmitriptan is a synthetic tryptamine derivative and 
appears as a white powder that is partially soluble in water. 
Drug class   : Antimigraine agents. 
Bioavailability  : 40% Oral. 
Protein binding  : 25%. 
Absorption   : Zolmitriptan is well absorbed after oral administration. 
Zolmitriptan displays linear kinetics over the dose range of 2.5 to 50 mg. 
Distribution   : Mean absolute bioavailability is approximately 40%. 
The mean apparent volume of distribution is 7.0 L/kg. Plasma protein binding of 
Zolmitriptan is 25% over the concentration range of 10- 1000 mg/ml. 
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Metabolism   : Hepatic (CYP1A2-mediated, to active metabolite). 
Zolmitriptan is converted to an active N-desmethyl metabolite; the metabolite 
concentrations are about two-thirds that of zolmitriptan. Because the 5HT1B/1D 
potency of the metabolite is 2 to 6 times that of the parent compound, the metabolite 
may contribute a substantial portion of the overall effect after zolmitriptan 
administration. 
Excretion: Renal (65%) and faecal (35%). Mean total plasma clearance is 31.5 
mL/min/kg, of which one-sixth is renal clearance. The renal clearance is greater than 
the glomerular filtration rate suggesting renal tubular secretion. 
Mechanism of action : Zolmitriptan is a new serotonergic agonist with excellent oral 
bioavailability exhibiting a potent symptomatic antimigraine effect. Zolmitriptan is a 
selective agonist of 5-HT1B/D receptors. 5-HT1B receptors are concentrated in the 
wall of the cranial extra cerebral arteries. 5-HT1D receptors are located on the 
trigeminal terminals which receive pain from the leptomeningeal vessels. Migraine 
pain has its origin on cranial vessels. In fact, during a migraine attack the trigemino 
vascular system, which is composed by the cranial vessels and its trigeminal 
terminals, is activated. The activation of this system induces both dilatation and 
aseptic inflammation of cranial vessels. Zolmitriptan blocks both vascular 
phenomena. Its agonist action upon the 5-HT1D receptor ends the aseptic 
inflammation by inhibiting the release of vasoactive peptides. The dilatation of 
meningeal vessels disappears due to the stimulation of Zolmitriptan of 5-HT1B 
receptors. As this drug crosses the blood brain barrier, Zolmitriptan has both 
peripheral and central actions over the spinal trigeminal nucleus, which is rich in 5-
HT1B/D receptors. Thus, the mechanism of action of Zolmitriptan is double. On the 
one hand, Zolmitriptan acts peripherally inhibiting dilatation and inflammation of 
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cranial vessels. On the other, Zolmitriptan exhibits a central nociceptive action in the 
brainstem nuclei. This dual action of Zolmitriptan on migraine pain is completed with 
its beneficial effects on nausea and vomiting, due to its binding to the nucleus of the 
tract us solitaries, the centre for control of vomiting. 
Brand names   : Zomig, Zomig-ZMT. 
Uses    : Migraines, Cluster headaches and cyclic vomiting 
syndrome. 
Indications and usage : Zolmitriptan is indicated for the acute treatment of 
migraine with or without aura in adults.  
Limitation of use  : Only use Zolmitriptan if a clear diagnosis of migraine 
has been established. If a patient has no response to Zolmitriptan treatment for the 
first migraine attack, reconsider the diagnosis of migraine before Zolmitriptan is 
administered to treat any subsequent attacks. Zolmitriptan is not indicated for the 
prevention of migraine attacks. Safety and effectiveness of Zolmitriptan have not been 
established for cluster headache. 
Dosing in Patients with Hepatic Impairment 
The recommended dose of Zolmitriptan in patients with moderate to severe 
hepatic impairment is 1.25 mg because of increased Zolmitriptan blood levels in these 
patients and elevation of blood pressure in some of these patients. Limit the total daily 
dose in patients with severe hepatic impairment to not more than 5 mg per day.  
Contraindications 
 Ischemic coronary artery disease (angina pectoris, history of myocardial 
infarction, or documented silent ischemia), 
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 Wolff-Parkinson-White Syndrome or arrhythmias, 
 History of stroke, transient ischemic attack (TIA), or history of hemiplegic or 
basilar migraine because these patients are at a higher risk of stroke, 
 Peripheral vascular disease (PVD), 
 Ischemic bowel disease, 
 Uncontrolled hypertension. 
Medication Overuse Headache  
Overuse of acute migraine drugs (e.g. ergotamine, triptans, opioids, or a 
combination of drugs for 10 or more days per month) may lead to exacerbation of 
headache (medication overuse headache). Detoxification of patients, including 
withdrawal of the overused drugs, and treatment of withdrawal symptoms (which 
often includes a transient worsening of headache) may be necessary. 
Adverse Reactions 
The following adverse reactions are described elsewhere in other sections of the 
prescribing information: 
 Myocardial Ischemia, Myocardial Infarction, and Prinzmetal Angina. 
 Arrthymias. 
 Chest and or Throat, Neck and Jaw Pain/Tightness/Pressure. 
 Cerebrovascular Events. 
 Other Vasospasm Reactions. 
 Medication Overuse Headache. 
 Serotonin Syndrome. 
 Increase in Blood Pressure. 
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DRUG INTERACTIONS 
Zolmitriptan is contraindicated to patients to use along with the following class of 
drugs  
 Ergot-containing Drugs,  
 MAO-A Inhibitors , 
 5-HT1B/1D agonists , 
 Selective Serotonin Reuptake Inhibitors and Serotonin Norepinephrine 
Reuptake Inhibitors and  
 Cimetidine. 
EXCIPIENT PROFILE 
5.2 CITRIC ACID 
Chemical structure  
 
Non-proprietary names 
BP: Citric acid monohydrate 
JP: Citric acid 
PhEur: Acidumcitricummonohydricum 
USP: Citric acid 
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Synonyms 
E330, 2-hydroxypropane-1,2,3-tricarboxylic acid monohydrate. 
Functional Category 
Acidifying agent, antioxidant, buffering agent, chelating agent and flavour enhancer. 
Applications in Pharmaceutical Formulation or technology: 
Citric acid is widely used in pharmaceutical formulations and food products, primarily 
to adjust the pH of solutions. It has also been used experimentally to adjust the pH of 
tablet matrices in enteric coated formulations for colon-specific drug delivery. Citric 
acid monohydrate is used in the preparation of effervescent granules, while anhydrous 
citric acid is widely used in the preparation of effervescent tablets. Citric acid has also 
been shown to improve the stability of spray dried insulin powder in inhalation 
formulations. 
In food products, citric acid is used as a flavour enhancer for its teat, acidic taste. 
Citric acid monohydrate is used as a sequestering agent and antioxidant synergist. It is 
also a component of anti-coagulant citrate solutions. Therapeutically, preparations 
containing citric acid have been used to dissolve renal calculi. 
Use Concentration (%) 
Buffer solutions 0.1-2.0 
Flavor enhancer for liquid formulations 0.3-2.0 
Sequestering agent 0.3-2.0 
Table 2.Uses of Citric acid at various concentrations. 
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Description 
Citric acid monohydrate occurs as colourless or translucent crystals, or as a white 
crystalline, efflorescent powder. It is odourless and has a strong acidic taste. The 
crystal structure is orthorhombic. 
Typical Properties 
Acidity/alkalinity   :  pH 2.2 (1% w/v aqueous solution) 
Density    : 1.542 g/cm
3 
Hygroscopicity:  at relative humidities less than about 65%, citric acid monohydrate 
effloresces at 25ºC, the anhydrous acid being formed at relative humidities less than 
about 40%. At relative humidities between about 65% and 75%, citric acid 
monohydrate absorbs insignificant amounts of citric acid monohydrate absorbs 
insignificant amounts of moisture, but under more humid conditions substantial 
amounts of water are absorbed. 
Melting point   :  100 ºC (soften at 75 ºC) 
Solubility:  Soluble 1 in 1.5 parts of ethanol (95%) and 1 in less than 1 part of water; 
sparingly soluble in ether. 
Viscosity (dynamic)  :  6.5mPa s (6.5 cP) for a 50% w/v aqueous  
     solution 35 ºC. 
Incompatibilities 
Citric acid is incompatible with potassium tartarate, alkali and alkaline earth 
carbonates and bicarbonates, acetates and sulfides. Incompatibilities also include 
oxidizing agents, bases, reducing agents, and nitrates.  It is potentially explosive in 
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combination with metal nitrates. On storage, sucrose may crystallize from syrups in 
the presence of citric acid. 
Related Substances 
Anhydrous citric acid ; fumaric acid; malic acid ; sodium citrate dihydrate ; tartaric 
acid. 
5.3 COLLOIDAL SILICON DI OXIDE
 
Chemical structure 
 
Non Proprietary Names 
BP: Colloidal anhydrous silica 
PhEur: Silica colloidalisanhydrica 
USPNF: Colloidal Silicon dioxide 
Synonym 
Aerosi, Cob-O-Sil M-5P, colloidal silica, fumed silica, light anhydrous silicic acid, 
silicic anhydride, silicon dioxide fumed, wacker HDK. 
Functional category: 
Adsorbent, anticaking agent, emulsion stabilizer, glidants, suspending agent, tablet 
disintegrants, thermal stabilizer and viscosity-increasing agent. 
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Applications in Pharmaceutical Formulation or Technology: 
Colloidal silicon dioxide is widely used in pharmaceuticals, cosmetics, and food 
products; It’s small particle size and large specific surface area give it desirable flow 
characteristics that are exploited to improve the flow properties of dry powders in a 
number of processes such as tableting. 
Colloidal Silicon dioxide is also used to stabilize emulsions and as a thixotropic 
thickening and suspending agent in gets and semisolid preparations. In aerosols, other 
than those for inhalation, Colloidal Silicon dioxide is used to promote particulate 
suspension, eliminate hard settling, and minimize the clogging of spray nozzles. 
Colloidal Silicon dioxide is also used as a tablet disintegrants and as an adsorbent 
dispersing agent for liquids in powders. Colloidal silica di oxide is used in 
suppositories for retarding the release profile. 
Description 
Colloidal silicon dioxide is sub microscopic fumed silica with a particle size of about 
15nm. It is a light, loose, bluish-white-coloured, odourless, tasteless, non-gritty 
amorphous powder. 
Typical Properties 
Acidity/alkalinity  :  pH 3.5-4.4 (4% w/v aqueous dispersion) 
Density (bulk)   : 0.029-0.042g/cm
3
 
Flowability   :  35.52% 
Particle size distribution :  7-16nm 
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Incompatibilities: 
Incompatible with diethylstilbestrol preparations. 
5.4 PANEXCEA ODT 
Product Composition 
PanExcea MC200G performance excipient contains a polyhydric sugar alcohol 
(mannitol) and a proprietary silicate salt (Calcium silicate). The novel Particle 
morphology makes it an excellent building block for orally disintegrating tablet 
applications. 
Description 
• Appearance   : Odourless, white crystalline powder 
• Morphology   :  Dense spherical particle 
• Particle Morphology 
• Particle Size Distribution  
 % Cumulative retained on 60 mesh 1.7% 
 % Cumulative retained on 200 mesh 77.0% 
 % Cumulative retained on 270 mesh 86.8% 
 d50 -  103 microns 
• Bulk Density   :  0.64 g/cc 
• Tapped Density   :  0.80 g/cc 
• Compressibility(Carr Index)   :  19.4 
• Hausner’s Ratio  :  1.21 
• Loss on Drying  :  4% 
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Increased Revenues and Shortened Time to Market 
PanExcea performance excipients improve supply chain, manufacturing and 
regulatory efficiencies — speeding your product to market while reducing your 
ownership costs and increasing your revenues. 
• Eliminates Oral Disintegrating Tablet (ODT) technology licensing 
• Formulation flexibility and scalability allowing: 
 Manipulation of excipient functionality 
 Masking of undesirable properties of the individual excipients 
 Addition of taste masking or other auxiliary excipients 
• Simplified tableting processes utilizing conventional direct compression equipment 
• Delivers tablets of optimal strength and stability, enabling use of conventional 
packaging. 
Application 
PanExcea™ performance excipients for orally disintegrating tablet applications act as 
a building block that enables the rapid disintegration of a tablet, in the oral cavity 
without water, while providing excellent mouth feel. 
• Tablet cost 5 to 10 times lower than conventional ODT technology. 
• Rapid and complete disintegration with no residue. 
• High Active Pharmaceutical Ingredient (API) loading capacity. 
• Potential to reduce tablet size and total volume of excipient. 
• Completely disintegrates in less than 30 seconds. 
• Smooth, creamy mouth feel. 
• Increases drug loading capability as a result of the novel particle morphology. 
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5.5 PHARMABURST 
Pharmaburst is a Quick Dissolving delivery system in which there is addition of 
active drug in a dry blend with Pharmaburst excipients and compress by tablet 
machine. Pharmaburst was found to be significantly more compactable, less friable, 
and more rapidly disintegrating. Pharmaburst is a coprocessed excipient system with 
specific excipients, which allows rapid disintegration and low adhesion to punches. 
Pharmaburst is smooth and creamy and helps to mask taste and grittiness of the 
actives. Main advantages Pharmaburst is highly compatible, rapid disintegration and 
cost effective 
Description 
Physical state   :  Solid 
Appearance   :  White to off-white, free-flowing powder 
Color    :  White 
Loss on drying   : NMT 3.0% 
Bulk Density   :  0.31 – 0.51 g/mL 
Tapped Density  : 0.38 – 0.68 g/mL 
Total Polyol Content (db) :  73.8 – 93.8% 
% retain on a #20 U.S. sieve :  NMT 1 
% through a #325 U.S. sieve :  NMT 18 
Melting point   :  330.8°F (164 -169°C) 
Boiling point    :  563°F (290 -295°C) decomposes 
Flash point    : > 300.2°F (149°C) 
Auto-ignition temperature  :  860°F (460°C) 
Solubility    :  Soluble 
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Storage conditions   :  Store at room temperature. Keep container 
tightly closed. 
Incompatible products :  Strong bases, Strong acids, Strong oxidizing 
agents. 
Incompatible materials :  Sources of ignition, direct sunlight.  
5.6 PEARLITOL® FLASH 
Pearlitol® Flash is a compound dedicated to orodispersible tablets obtained by 
Direct Compression. 
Description 
White, odourless, slightly sweet tasting, crystalline powder 
Functional Category 
Rapid Release Agent, Disintegrant 
Particle Size 
200 µm 
Advantages 
 Pleasing taste  
 A fast melting in the mouth  
 An easy DC tableting process  
 A robust DC excipient  
 A surprisingly simple formulation 
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5.7 PEPPERMINT FLAVOR 
Description:   Brown fine powder from leaf of mentha. 
Functional Category: Flavouring agent. 
Applications in pharmaceutical Formulation or technology: 
 Peppermint flavour is used in medicine to mask or impart taste to medications. 
A flavour, as used in the pharmaceutical industry for inactive ingredients, refers to 
natural or artificial tastes, which may include fragrances and colours of the flavouring. 
Flavours are used for orally consumed products such as syrups, chewable tablets, 
suspensions, or gums that impart beneficial therapeutic effect, as well. Peppermint is a 
common and popular flavour used in medications. 
5.8 SODIUM STEARYL FUMARATE 
Chemical structure 
 
Nonproprietary Names 
BP: Sodium Stearyl Fumarate 
PhEur: Natriistearylisfumaras 
USPNF: Sodium Stearyl Fumarate 
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Synonym 
Fumaric acid, octadecyl ester, sodium salt, pruv; sodium monostearyl Fumarate 
Functional Category: 
Tablet and capsule lubricant 
Applications in pharmaceutical Formulation or technology 
Sodium Stearyl Fumarate is used as a lubricant in capsule and tablet formulation at 
0.5-2.0% ww concentration. It is also used in certain food applications 
Description 
Sodium Stearyl Fumarate is used as a fine, white powder with agglomerates of flat, 
circular-shaped particles. 
Typical Properties 
Acidity/alkalinity  : pH 8.3for a 5%w/v aqueous solution at 90ºC. 
Density   : 1.107g/cm
3 
Bulk density   :  0.2-0.35 g/cm
3 
Tapped density  : 0.3-0.5 g/cm
3
 
Melting point   :  224-245ºC(with decomposition) 
Incompatibilities 
Sodium Stearyl Fumarate is reported to be incomparible with chlorhexidine acetate. 
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5.9 SUCRALOSE
 
Chemical structure 
 
Nonproprietary Names 
USPNF: Sucralose 
Synonym 
Splenda; TGS; 1’,4’,6’-trichlorogalactosucrose; 4,1’,6’-tri-chloro-4,1’,6’-trideoxy-
galacto-sucrose. 
Functional Category: 
Sweetening agent 
Applications in pharmaceutical Formulation or technology: 
Sucralose is used as a sweetening agent in beverages, foods, and pharmaceutical 
applications. It has a sweetening power approximately300-1000 times that of sucrose 
and has no aftertaste. It has no nutritional value, is noncarcinogenic, and produces no 
glycemic response. 
Description 
Sucralose is a white to off-white coloured, free-flowing and crystalline powder. 
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Typical Properties 
Acidity/alkalinity :  pH 5-6 (10% w/v aqueous solution at 20ºC) 
Density (bulk)  :  0.35 g/cm
3
 
Density (tapped) :  0.62 g/cm
3
 
Density (true)  :  1.63g/cm
3
 
Melting point  : 130ºC (for anhydrous crystalline form); 
     36.5ºC  (for pentahydrate). 
Particle size distribution:  90% <12µm in size. 
5.10 MANNITOL 
Chemical structure 
 
Nonproprietary Names 
BP: Mannitol 
JP: D-Mannitol  
PhEur: Mannitolum 
USP: Mannitol 
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Synonyms 
Cordycepic acid; C*PharmMannidex; E421; manna sugar; D-mannite; mannite; 
Mannogem; Pearlitol 
Chemical Name and CAS Registry Number 
 D-Mannitol [69-65-8] 
Functional Category Diluent; 
Diluent for lyophilized preparations; sweetening agent; tablet and capsule diluent; 
tonicity agent; 
Applications in Pharmaceutical Formulation or Technology; 
 Mannitol is widely used in pharmaceutical formulations and food products. In 
pharmaceutical preparations it is primarily used as a diluent (10–90% w/w) in tablet 
formulations, where it is of particular value since it is not hygroscopic and may thus 
be used with moisture-sensitive active ingredients. Mannitol may be used in direct-
compression tablet applications, for which the granular and spray-dried forms are 
available, or in wet granulations. Granulations containing mannitol have the 
advantage of being dried easily. Specific tablet applications include antacid 
preparations, glyceryl trinitrate tablets, and vitamin preparations. Mannitol is 
commonly used as an excipient in the manufacture of chewable tablet formulations 
because of its negative heat of solution, sweetness, and ‘mouth feel’. In lyophilized 
preparations, mannitol (20–90% w/w) has been included as a carrier to produce a stiff, 
homogeneous cake that improves the appearance of the lyophilized plug in a vial. A 
pyrogen-free form is available specifically for this use. Mannitol has also been used to 
prevent thickening in aqueous antacid suspensions of aluminium hydroxide  
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Description 
 Mannitol is D-Mannitol. It is a hexahydric alcohol related to mannose and is isomeric 
with sorbitol. Mannitol occurs as a white, odourless, crystalline powder, or free-
flowing granules. It has a sweet taste, approximately as sweet as glucose and half as 
sweet as sucrose, and imparts a cooling sensation in the mouth. Microscopically, it 
appears as orthorhombic needles when crystallized from alcohol. Mannitol shows 
polymorphism. 
Typical Properties Compressibility: 
1. Bulk density       : 0.430 g/cm3 for powder; 0.7 g/cm3 for granules.  
2. Tapped density   : 0.734 g/cm3 for powder; 0.8 g/cm3 for granules.  
3. True density        : 1.514 g/cm3  
4. pKa = 13.5 at 188C Flash point 
Stability and Storage Conditions; 
 Mannitol is stable in the dry state and in aqueous solutions. Solutions may be 
sterilized by filtration or by autoclaving and if necessary may be autoclaved 
repeatedly with no adverse physical or chemical effects. In solution, mannitol is not 
attacked by cold, dilute acids or alkalis, or by atmospheric oxygen in the absence of 
catalysts. Mannitol does not undergo Maillard reactions. The bulk material should be 
stored in a well-closed container in a cool, dry place. 
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Incompatibilities  
Mannitol solutions, 20% w/v or stronger, may be salted out by potassium chloride or 
sodium chloride. Precipitation has been reported to occur when a 25% w/v mannitol 
solution was allowed to contact plastic. Sodium cephapirin at 2 mg/ml and 30 mg/ml 
concentration is incompatible with 20% w/v aqueous mannitol solution. Mannitol is 
incompatible with xylitol infusion and may form complexes with some metals such as 
aluminium, copper, and iron. Reducing sugar impurities in mannitol have been 
implicated in the oxidative degradation of a peptide in a lyophilized formation. 
Mannitol was found to reduce the oral bioavailability of cimetidine compared to 
sucrose. 
Safety  
 Mannitol is a naturally occurring sugar alcohol found in animals and plants; it is 
present in small quantities in almost all vegetables. Laxative effects may occur if 
mannitol is consumed orally in large quantities. If it is used in foods as a bodying 
agent and daily ingestion of over 20 g is foreseeable, the product label should bear the 
statement ‘excessive consumption may have a laxative effect’. After intravenous 
injection, mannitol is not metabolized to any appreciable extent and is minimally 
reabsorbed by the renal tubule, about 80% of a dose being excreted in the urine in 3 
hours. A number of adverse reactions to mannitol have been reported, primarily 
following the therapeutic use of 20% w/v aqueous intravenous infusions. The quantity 
of mannitol used as an excipient is considerably less than that used therapeutically 
and is consequently associated with a lower incidence of adverse reactions. However, 
allergic, hypersensitive-type reactions may occur when mannitol is used as an 
excipient 
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An acceptable daily intake of mannitol has not been specified by the WHO since the 
amount consumed as a sweetening agent was not considered to represent a hazard to 
health. LD50 (mouse, IP): 14 g/kg LD50 (mouse, IV): 7.47 g/kg LD50 (mouse, oral): 
22 g/kg LD50 (rat, IV): 9.69 g/kg LD50 (rat, oral): 13.5 g/kg. 
Handling Precautions; 
 Observe normal precautions appropriate to the circumstances and quantity of material 
handled. Mannitol may be irritant to the eyes; eye protection is recommended 
Regulatory Status GRAS listed. 
 Accepted for use as a food additive in Europe, Included in the FDA Inactive 
Ingredients Guide (IP, IM, IV, and SC injections; infusions; buccal, oral and 
sublingual tablets, powders and capsules; ophthalmic preparations; topical solutions). 
Included in non-parenteral and parenteral medicines licensed in the UK; 
Related Substances 
 Sorbitol 
5.11 ETHYL CELLULOSE 
Chemical structure 
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Nonproprietary Names  
BP: Ethylcellulose  
PhEur: Ethylcellulosum 
 USPNF: Ethylcellulose  
Synonyms 
Aquacoat ECD; Aqualon; E462; Ethocel; Surelease. 
Chemical Name and CAS Registry Number 
 Cellulose ethyl ether [9004-57-3]  
Empirical Formula and Molecular Weight  
Ethylcellulose with complete ethoxyl substitution is C12H23O6 (C12H22O5) 
nC12H23O5 where n can vary to provide a wide variety of molecular weights. 
Ethylcellulose, an ethyl ether of cellulose, is a long-chain polymer of 
anhydrousglucose units joined together by acetal linkages. 
Functional Category 
 Coating agent; flavouring fixative; tablet binder; tablet filler; viscosity-increasing 
agent. 
Applications in Pharmaceutical Formulation or Technology 
Ethylcellulose is widely used in oral and topical pharmaceutical formulations. The 
main use of ethylcellulose in oral formulations is as a hydrophobic coating agent for 
tablets and granules. Ethylcellulose coatings are used to modify the release of a drug, 
to mask an unpleasant taste, or to improve the stability of a formulation; for example, 
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where granules are coated with ethylcellulose to inhibit oxidation. Modified release 
tablet formulations may also be produced using ethylcellulose as a matrix former. 
Ethylcellulose, dissolved in an organic solvent or solvent mixture, can be used on its 
own to produce water-insoluble films. Higher-viscosity ethylcellulose grades tend to 
produce stronger and more durable films. Ethylcellulose films may be modified to 
alter their solubility, by the addition of hypromellose or a plasticizer. An aqueous 
polymer dispersion (or latex) of ethylcellulose such as Aquacoat ECD (FMC 
Biopolymer) or Surelease (Colorcon) may also be used to produce ethylcellulose 
films without the need for organic solvents. Drug release through ethylcellulose-
coated dosage forms can be controlled by diffusion through the film coating. This can 
be a slow process unless a large surface area (e.g. pellets or granules compared with 
tablets) is utilized. In those instances, aqueous ethylcellulose dispersions are generally 
used to coat granules or pellets. Ethylcellulose-coated beads and granules have also 
demonstrated the ability to absorb pressure and hence protect the coating from 
fracture during compression. High-viscosity grades of ethylcellulose are used in drug 
microencapsulation. Release of a drug from an ethylcellulose microcapsule is a 
function of the microcapsule wall thickness and surface area. In tablet formulations, 
ethylcellulose may additionally be employed as a binder, the ethylcellulose being 
blended dry or wet-granulated with a solvent such as ethanol (95%). Ethylcellulose 
produces hard tablets with low friability, although they may demonstrate poor 
dissolution. Ethylcellulose has also been used as an agent for delivering therapeutic 
agents from oral (e.g. dental) appliances. In topical formulations, ethylcellulose is 
used as a thickening agent in creams, lotions, or gels, provided an appropriate solvent 
is used. Ethylcellulose has been studied as a stabilizer for emulsions. Ethylcellulose is 
additionally used in cosmetics and food products. 
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Description 
 Ethylcellulose is a tasteless, free-flowing, and white to light tan colored powder. 
Typical Properties 
Bulk density: 0.4 g/cm3  
Glass transition temperature: 129–1338C  
Moisture content: Ethylcellulose absorbs very little water from humid air or during 
immersion, and that small amount evaporates readily. 
Stability and Storage Conditions 
 Ethylcellulose is a stable, slightly hygroscopic material. It is chemically resistant to 
alkalis, both dilute and concentrated, and to salt solutions, although it is more 
sensitive to acidic materials than are cellulose esters. Ethylcellulose is subject to 
oxidative degradation in the presence of sunlight or UV light at elevated temperatures. 
This may be prevented by the use of antioxidant and chemical additives that absorb 
light in the 230–340 nm range. Ethylcellulose should be stored at a temperature not 
exceeding 328C (908F) in a dry area away from all sources of heat. It should not be 
stored next to peroxides or other oxidizing agents. 
Incompatibilities 
Incompatible with paraffin wax and microcrystalline wax 
Safety 
Ethylcellulose is widely used in oral and topical pharmaceutical formulations. It is 
also used in food products. Ethylcellulose is not metabolized following oral 
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consumption and is therefore a noncalorific substance. Because ethylcellulose is not 
metabolized it is not recommended for parenteral products; parenteral use may be 
harmful to the kidneys. 
Ethylcellulose is generally regarded as a nontoxic, nonallergenic, and nonirritating 
material. As ethylcellulose is not considered to be a health hazard, the WHO has not 
specified an acceptable daily intake. LD50 (rabbit, skin) : >5 g/kg (30) LD50 (rat, 
oral) : >5 g/kg 
 Handling Precautions 
It is important to prevent fine dust clouds of ethylcellulose from reaching potentially 
explosive levels in the air. Ethylcellulose is combustible. Ethylcellulose powder may 
be an irritant to the eyes and eye protection should be worn. 
Regulatory Status GRAS listed.  
Accepted for use as a food additive in Europe. Included in the FDA Inactive 
Ingredients Guide (oral capsules, suspensions and tablets; topical emulsions and 
vaginal preparations). Included in non-parenteral medicines licensed in Europe. 
Included in the Canadian List of Acceptable Non medicinal Ingredients. 
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6. MATERIALS AND MEHODS 
6.1 Materials used 
S.NO Ingredients Manufacturer 
1.  Zolmitriptan USP Aurobindo Pharma 
2.  Pharmaburst SPI Pharma 
3.  Pearlitol Flash RoquettePharma 
4.  PanExcea ODT Avantor Performance Materials 
5.  Peppermint Flavour 501500 TP0504 FirmenichPharma 
6.  Citric Acid Anhydrous, USP Avantor Performance Materials 
7.  Sucralose JK Sucralose 
8.  Colloidal Silicon Dioxide (100) EvonikPharma 
9.  Sodium Stearyl Fumarate (Pruv) JRS Pharma 
10.  Mannitol Global pharma 
11.  Ethyl cellulose Shreejipharma international 
12.  Orange flavour powder Prakash chemicals agencies 
13.  Pearlitol Flash FirmenichPharma 
Table 3. Materials used in formulations 
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6.2 Instruments used 
S.NO Name of the instrument Manufacturer 
1.  Analytical balance, Essae -teraoku Ltd 
2.  Sieves #40 and #60 mesh, Cansons 
3.  Double cone blender 5L, Pharma pack 
4.  compression machine, Cadmach 
5.  Digital vernier calliper, Lab India 
6.  Friability tester, Electrolab 
7.  Hardness tester, Erweka 
8.  Tap Density Tester, Electrolab 
9.  Disintegration Tester, Electrolab 
10.  Moisture analyser, Ohaus 
11.  Vibrosifter, Cansons 
12.  Funnel and stand for Angle of repose, Borosil 
13.  Dissolution test apparatus, Labindia, disso 2000 
14.  Water's HPLC. Elico Li 120 
Table 4. Instruments used in Formulation 
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6.3PREPARATION OF STANDARD CURVE FOR ZOLMITRIPTAN 
PREPARATION OF PH 6.8 BUFFER (phosphate buffer) 
 
27.218 gm of potassium dihydrogen orthophosphate was dissolved in 1000 
ml of distilled water. And to prepare 0.1 N sodium hydroxide solution. Then 
from this Potassium dihydrogen orthophosphate solution 250 ml was taken 
and mixed with 112 ml of 0.1 N Sodium hydroxide solutions. Finally to 
make up 1000 ml by using distilled water. 
PREPARATION OF STANDARD CURVE FOR ZOLMITRIPTAN 
100 mg of Zolmitriptan was accurately weighed and dissolved in small 
portion of phosphate buffer pH 6.8 in a 100 ml of volumetric flask and the 
volume was made up to 100 ml with buffer. This is the primary stock 
solution. From the primary stock solution 10 ml was accurately pippetted out 
and transferred into a 100 ml volumetric flask. Then the volume was made 
up to 100 ml with buffer. From the secondary stock solution aliquots 
equivalent to 2-10 mcg (2ml, 4ml, 6ml, 8ml, and 10 ml) were pippeted out 
into a series of 10 with buffer. The absorbance of above set solutions was 
against the phosphate buffer pH 6.8 as blank at 248nm. Then calibration 
curve was plotted taking concentration on X-axis and absorbance on Y-axis. 
6.4 Preformulation  
It is the first step in rational development of dosage forms of drug substance. 
Preformulation testing is defined as investigation of physical and chemical properties 
of a drug substance alone and when combined with excipients. The overall objective 
of preformulation testing is to generate information useful to the formulator in 
developing stable and bio-available dosage forms that can be mass-produced. 
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Preformulation investigations are designed to identify those physicochemical 
properties and excipients that may influence the formulation design, method of 
manufacture and pharmacokinetic biopharmaceutical properties of the resulting 
product. 
 Preformulation parameters 
6.4.1 Organoleptic properties 
This includes recording of colour, odour and taste of the drug using 
descriptive terminology. Record of colour of early batches is very useful in 
establishing appropriate specifications for later production. Drugs generally have a 
characteristic odour and taste. Unpleasant ones are masked later during formulation. 
Organoleptic Parameter Observation 
Colour White 
Odour Peppermint odour 
Taste Peppermint flavour 
Table 5. Organoleptic parameters and its observations 
6.4.2 Physicochemical characterization: 
Density measurement: 
Granules density may influence compressibility, tablet porosity, dissolution and other 
properties. Different types of density calculation were done to characterize the drug 
and its flow property. Generally two types of density are determined i.e., bulk density 
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and tapped density. The methods followed for calculation of the above two densities 
are determined by the following ways. 
Bulk density:  
 It is a measure used to describe the packing of particles or granules. An 
accurately weighed quantity of powder, which was previously passed through sieve 
#40 [USP] and carefully poured bed, was made uniform without disturbing. Then 
volume measure was called as the bulk volume and the bulk density is calculated by 
following formula. 
Bulk density= weight of powder / Bulk volume 
Tapped density: 
 After measuring the bulk volume the same measuring cylinder was set into tap 
density apparatus. The tap density apparatus was set to300 taps drop per minute and 
operated for 500 taps. Volume was noted as (Va) and again tapped for750 times and 
volume was noted as (Vb). If the difference between Va and Vb not greater than 2% 
then Vb is considered as final tapped volume. The tapped density is calculated by the 
following formula. 
Tapped density= Weight of powder /Tapped volume 
6.4.3 Flow properties:  
The flow properties from a material result from many forces. There are many 
types of forces hat can act between solid particles: frictional forces, surface tension 
forces, mechanical forces caused by interlocking of particles of irregular shapes, 
electrostatic forces and cohesive or vander vaals forces. These forces can effect 
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granule properties such as particle size, particle size distribution, particle shape, 
surface texture or roughness, residual surface energy and surface area. 
6.4.4 Compressibility index: 
 Pharmaceutical powders are broadly classified into free flowing and cohesive.  
Powders are more often compressed into tablets using a pressure of 5kg/cm
2
.  This is 
called compression or compaction. During this process the porosity of the powder 
changes. The compression properties of most drugs are very poor.  Therefore 
compression vehicles such as lactose, calcium phosphate and microcrystalline 
cellulose are included in tablet formulations.  Normally low dose drugs (<50mg) are 
prepared by direct compression. Tablet materials should be plastic that is capable of 
undergoing permanent deformation yet exhibit brittleness.  Percentage compressibility 
also known as Carr’s consolidation index is indirectly related to the relative flow rate, 
cohesiveness and particle size.  It is a simple, fast and popular method for predicting 
powder flow characteristics. 
Percentage  compressibility Flowability 
5-10 Excellent 
12-16 Good 
18-21 Fair 
23-25 Poor 
Table 6; Percentage compressibility and corresponding Flowability 
Carr’s consolidation index = [(Tapped density-Fluff density)/tapped density]*100  
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Compressibility index can be a measure of the potential strength that a powder could 
build up in its arch in a hopper and also the ease with which such an arch should be 
broken. 
6.4.5 Angle of repose 
The angle of Repose is defined as the maximum angle possible between the surface of 
a pile of powder and the horizontal plane.  
θ= Tan-1 (h/r) 
Where 
 ‘h’    =     height of the pile 
 ‘r’     =     radius of the pile 
Values of Ө are rarely less than 200, and values of up to 400 indicate reasonably flow 
potential. Above 50
0
, however, the powder flows only with great difficulty.  In 
general, the angle of repose increased with decreasing particle size. The addition of 
talk in low concentration decreases the repose angle, but in higher concentration it 
increases the angle.  
Flow Property Angle of Repose(degree) 
Excellent 25-30 
Good 31-35 
Fair – aid not needed 36-40 
Passable -  may hang up 41-45 
Poor – must agitate, vibrate 46-55 
Very poor 56-65 
Very very poor >66 
Table 7: Flow Properties and Corresponding Angles of Repose 
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6.4.6 Hausner’s ratio: 
It is the ratio of bulk volume or tapped density to bulk density. Hausner’s ratio is an 
important character to determine the flow property of powder and granules. Thiscan 
be calculated by the formula 
Hausner ‘s ratio=Tapped density/Bulk density 
Value<1.25 indicate good flow(=20% carr’s index) 
While>1.50 indicate poor flow(-35% carr’s index) 
Flow Character Hausner’s Ratio 
Excellent 1.2-1.3 
Good 1.3-1.4 
Fair 1.4-1.5 
Poor 1.5-1.6 
Table 8. Flow property and corresponding Hausner’s ratio. 
6.4.7 Particle size distribution 
Particle size distribution is a very important in process technique of final blend 
after blending. It is an important parameter to determine the amount of fines as well as 
particle with larger particle size in final blend. It also helps in keeping a check over 
uniformity of distribution of blend over various sizes while carrying out consecutive 
batches. Particle size determination was carried by arranging various sieves of sizes 
#20, #40, #60, #80, #100, #140, #200 and Pan (for finer particles which passes even 
#200 sieve) in ascending order (i.e.,#20 sieve lies on top and pan at the bottom). Then 
the final blend of accurately weighed quantity was placed on the top sieve. And the 
sieves are placed in vibrosifter and allowed to run at1.0 amplitude for 10 minutes. 
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After the procedure difference of initial and final weight of sieves were noted to 
calculate the percentage retention of the blend in various sieves. 
6.5. DRUG EXCIPIENT COMPATABILITY STUDY BY FTIR ANALYSIS 
Compatibility of the drug with excipients was determined by FT-IR spectral 
analysis, this study was carried out to detect any changes on chemical 
constitution of the drug after combined it with the excipients. 
Infrared spectra for pure Zolmitriptan, drug with polymers, and best formulation 
that determined to check the intactness of the drug in the formulation. 
The Table no- 14 shows the wave number for the characteristic bands in the 
infrared spectra of pure Zolmitriptan. 
6.6 PROCEDURE FOR PREPARATION OF ZOLMITRIPTAN – ETHYL 
CELLULOSE MIXTURE FOR TASTE MASKING 
 API is weighed accurately and sifted through # 40 mesh. 
 Ethyl cellulose is weighed accurately and dissolved in isopropyl alcohol in the 
required ratio (5:1, 5:2, and 5:3). 
 API is granulated with the ethylcellulose solution and initially air dried 
followed by drying with rapid drier. 
 The dried mixture is tested for taste evaluation (organoleptic character) orally 
and until the taste found satisfactory the concentration of ethyl cellulose 
against the API is increased. 
6.6.1 PROCEDURE FOR FORMULATION AND COMPRESSION OF 
TABLETS (FOR FORMULATION FZ1, FZ5, FZ6, FZ7, FZ8 AND FZ9) 
 All the ingredients were weighed accurately as per the formula made 
 Initially all the listed  ingredients were sifted through #40 mesh 
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 API mixture was added to the blend geometrically by mixing with the other 
excipients while sifting 
 Load the sifted ingredients in a 5L Double Cone Blender and blend for 5 
minutes at 15 RPM 
 Unload the blended materials and again sift through #40 mesh. 
 Load the sifted materials again in the 5L Double Cone Blender and blend for 
20 minutes at 15 RPM 
 Sift Colloidal Silicon Dioxide and Sodium Stearyl Fumarate through #60 
mesh 
 Blend the sifted materials along with blended materials in a 5L Double Cone 
Blender and blend for 5 minutes at 15 RPM 
 Compress the blended materials using 7.15 mm Round Flat Faced Bevel 
Edged Plain Tooling 
6.6.2 PROCEDURE FOR FORMULATION AND COMPRESSION OF 
TABLETS (FOR FORMULATIONFZ2, FZ3 AND FZ4) 
 All the ingredients were weighed accurately as per the formula made 
 Initially all the listed  ingredients were sifted through #40 mesh 
 API mixture was added to the blend geometrically by mixing with the other 
excipients while sifting 
 Load the sifted ingredients in a 5L High shear mixture granulator and 
granulate with purified water with impeller and chopper at high speed for three 
minutes. 
 Dry it in the rapid dryer until it reaches the LOD of 2.5%. 
 Unload the dried materials and again sift through #40 mesh. 
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 Load the sifted materials along with the extra granular material in the 5L 
Double Cone Blender and blend for 20 minutes at 15 RPM 
 Sift Colloidal Silicon (if applicable) Dioxide and Sodium Stearyl Fumarate 
through #60 mesh 
 Blend the sifted materials along with blended materials in a 5L Double Cone 
Blender and blend for 5 minutes at 15 RPM 
 Compress the blended materials using 7.15 mm Round Flat Faced Bevel 
Edged Plain Tooling 
6.6.3 BLENDING 
Blending (Pre Lubrication) 
The blending step involves mixing of additives using double cone blender (DCB). In 
this step all the ingredients are transferred into the DCB except the lubricating 
agents and the machine is allowed to rotate at the speed of 15±1RPMfor 5minutes. 
Then the blend is unloaded and sieved by using the sieve of #40 mesh. The sieved 
blend was again loaded into the blender and allowed to rotate for 25 minutes. The 
blend uniformity sample was taken at 20, 25 and 30 minutes from ten different 
positions using the sampling rod for optimizing the blending time for pre lubrication. 
6.6.4 BLENDING (LUBRICATION) 
Lubricating agents are added to the blend after sieving with #60 mesh. And the blend 
is allowed to rotate for 5 min for lubrication. The blend uniformity sample was taken 
at 4, 5 and 6 minutes from ten different positions using the sampling rod for optimizing 
the blending time for lubrication. 
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6.6.5 COMPRESSION 
Compression is done by using machine Cadmach compression machine which is 
double rotary having 16stations. Compression was carried as per BMR using 
standard concave shaped punches with hard chrome platedtips. 
Number of stations     : 16 
Type of tooling           : “D” type 
Procedure is done for description, average weight, disintegration time, friability,   
thickness and hardness. 
6.6.6 Formulation and their composition: 
S. No Composition 
Ratio 
(API: Ethyl cellulose: 
IPA) 
Inference form organoleptic 
evaluation by selected 
volunteers 
1 
Zolmitriptan 
5 : 1 : 1 
Bitterness was not efficiently 
.asked Ethyl cellulose 
Iso propyl alcohol 
2 
Zolmitriptan 
5 : 2 : 1 
Comparatively low, but 
bitterness still found. Ethyl cellulose 
Iso propyl alcohol 
3 
Zolmitriptan 
5 : 3 : 1 
Comparatively better taste. 
Ethyl cellulose 
Iso propyl alcohol 
Table: 9 Composition of unit dose of Zolmitriptan – ethylcellulose mixture for 
taste masking formulations 
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Various batches were planned and executed with the unit concentration of the 
ingredients used in the batch as shown in the table below. 
S. 
No 
Ingredients 
Fz1 
(mg) 
Fz2 
(mg) 
Fz3 
(mg) 
Fz4 
(mg) 
Fz5 
(mg) 
Fz6 
(mg) 
Fz7 
(mg) 
Fz8 
(mg) 
Fz9 
(mg) 
Intragranular Portion 
1 Zolmitriptan 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 5.00 
2 
Ethyl 
cellulose 
3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00 
3 
Iso propyl 
alcohol 
1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 
4 Mannitol 
109.
00 
109.
0 
104.0 99.00 - - - - - 
5 
Purified 
Water 
- 
10.0
0 
10.00 10.00 - - - - - 
6 
Pearlitol 
Flash 
- - - - 109.0 - - - - 
7 
Pharma 
Burst 
- - - - - 109.0 - - - 
8 
Pan Excea 
ODT 
- - - - - - 109.0 
107.
7 
106.5 
9 
Orange 
flavour 
1.25 1.25 1.25 1.25 - - - - - 
10 
Peppermint 
Flavour 
- - - - 1.25 1.25 1.25 1.25 1.25 
11 
Citric Acid 
Anhydrous, 
USP 
4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00 
12 Sucralose 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00 3.00 
Extragranular portion 
13 
Polyplasdo
neXL 10 
- - 5.00 10.00 - - - - - 
14 
Colloidal 
Silicon 
Dioxide 
(Aerosil 
200) 
- - - - 1.25 1.25 1.25 2.50 2.50 
15 
Sodium 
Stearyl 
Fumarate 
(Pruv) 
1.25 1.25 1.25 1.25 1.25 1.25 1.25 1.25 2.50 
16 Total 
125.
00 
125.
00 
125.
00 
125.
00 
125.
00 
125.
00 
125.
00 
125.
00 
125.
00 
table 10. Composition of unit dose of various Formulations Characteristics of final blend 
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6.7 Evaluation parameters 
Physical appearance 
The physical appearance of a tablet, its visual identity and over all “elegance” is 
essential for consumer acceptance. Included in this category are tablet sizes, shape, 
colour, presence or absence of any odour, taste, surface texture, physical flaws and 
consistency and legibility of any identification marking. 
Weight variation 
Twenty tablets were selected randomly from the lot and weighed individually 
to check for weight variation. Each tablet weight was then compared with average 
weight variation. Each tablet weight was then compared with average weight to 
ascertain the weight of the tablets within the permissible limits. Not more than two of 
the individual weights should deviate from the permissible limits. Not more than two 
of the individual weights should deviate from the average weight by more than 5% for 
>300mg tablets and none by more than double that percentage.  
Percentage deviation= [(Tablet weight- Average weight)/tablet weight] ×100 
S.No Weight(mg) 
Maximum percentage 
difference allowed 
1. 130 or Less 10 
2. 130 - 324 7.5 
3. More than 324 5 
Table 11; USP Specification for uniformity of weight 
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Loss on drying 
Loss on drying is an important parameter to determine the moisture intake by 
blend during processing. Limit on loss on drying is established from the sum of 
percentage moisture intake values of each excipient used in the process. Percentage 
moisture in take was determined during in process by using Ohaus Moisture Analyser. 
In which 1gm of blend was placed after tarring the instrument at 105°C in auto mode. 
Friability 
Friability test is performed to assess the effect of friction and shocks, which 
may often cause the tablet to chip, cap or break. Roche friabilator was used for the 
purpose. This device subjects number of tablets to the combined effect of abrasion 
and shock by utilizing a plastic chamber that revolves at 25 rpm dropping the tablets 
at a distance of 6 inches with each revolution. Pre-weighed sample of tablets were 
dusted and reweighed. Compressed tablets should not lose more than 1% of their 
weight. 
               Percentage friability = [(w2-w1)/w1]×100 
Where, W1 = Weight of tablets before test; W2= Weight of tablets after test 
Thickness 
The thickness was measured by using vernier calliper and values were 
tabulated. Ten tablets of each batch were measured. Average and standard deviation 
was calculated. 
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Hardness 
The hardness of tablet is an indication of its strength. Measuring the force 
required to break the tablet across tests it. The force is measured in kg and the 
hardness of about 3-5 kg/cm2 is considered to be satisfactory for uncoated tablets. 
Hardness of 10 tablets from each formulation is determined by Erweka hardness 
tester. 
Disintegration test 
Breaking of tablets into smaller particles or granules is known as 
disintegration and time taken for breaking of tablets in a suitable medium is called 
disintegration time (DT). This test is not applicable to modified-release tablets and 
tablets for use in the mouth. For those tablets for which the dissolution test is included 
in the individual monograph, the test for disintegration is not required. It is 
determined by USP apparatus (Electro lab Disintegration Tester). It consists of 6 glass 
tube each 3 inches long, open at top and has 10 mesh screens at the bottom end of 
basket rack. One tablet is placed in each tube and placed in a one litre beaker of water, 
simulated gastric fluid or simulated intestinal fluid at 37 ± 2oC. It moves up and down 
through a distances of 5 to 6 cm at 28 to 32 cpm.  
Uncoated tablet has disintegration time as low as 5 minutes. Majority of 
tablets has DT of 30 minutes. DT of enteric coated tablet is one hour in simulated 
gastric fluid and two hours in simulated intestinal fluid.  DT for dispersible and 
soluble tablets is within 3 minutes. 
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Contend uniformity 
Uniformity of contend is a pharmaceutical analysis parameter for the quality control 
of tablets or capsules. Multiple capsules or tablets are selected at random and a 
suitable analytical method is applied to assay the individual content of the active 
ingredient in each tablet or capsule. 
Blend uniformity 
It is to check the formulation in blending process can find the drug substance which 
distrusted with all other ingredients evenly ratio of the blend that course in 
granulation process. 
Stability Studies 
The optimized formulation of ODTs is subjected to stability study as per ICH 
guidelines to assess their stability with respect to their physical appearance and 
release characteristics. 
Moisture 
Clean the container with lid dries it and weighs it (W1).Take a specimen of the 
sample in the container and weigh with lid (W2).Keep the container in the oven with 
lid removed. Dry the specimen to constant weight maintaining the temperature 
between 60º C to 100º C for a period varying with the type of sample but usually 16 
to 24 hours. Record the final constant weight (W3) of the container with dried 
sample. 
Assay 
Different aliquots (mL) of 200 μg mL−1 ZMT solution were accurately 
measured and transferred into a series of 10 mL volumetric flasks, and the total 
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volume was brought to 4.5 mL with methanol. To each flask 1 mL of 4% vanillin was 
added followed by 1 mL of concentrated H2SO4 and kept aside for 10 minutes; finally 
the volume was brought up to mark with methanol. The absorbance was measured at 
580 nm versus reagent blank. A calibration graph was prepared by plotting the 
measured absorbance versus concentration. The concentration of the unknown was 
read from the calibration graph or computed from the regression equation derived 
using the Beer’s law data. 
Total impurity 
           A registration application should include documented evidence that the 
analytical procedures are validated and suitable for the detection and quantification of 
impurities. Technical factors (e.g., manufacturing capability and control 
methodology) can be considered as part of the justification for selection of alternative 
thresholds based on manufacturing experience with the proposed commercial process. 
The use of two decimal places for thresholds does not necessarily reflect the precision 
of the analytical procedure used for routine quality control purposes. Thus, the use of 
lower precision techniques (e.g., thin-layer chromatography) can be appropriate where 
justified and appropriately validated. Differences in the analytical procedures used 
during development and those proposed for the commercial product should be 
discussed in the registration application. The quantization limit for the analytical 
procedure should be not more than (≤) the reporting threshold. 
The drug substance can be used as a standard to estimate the levels of impurities. In 
cases where the response factors of a drug substance and the relevant impurity are not 
close, this practice can still be appropriate, provided a correction factor is applied or 
the impurities are, in fact, being overestimated. Acceptance criteria and analytical 
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procedures used to estimate identified or unidentified impurities can be based on 
analytical assumptions (e.g., equivalent detector response). These assumptions should 
be discussed in registration applications. 
6.8 Analytical methods 
Method of analysis for Dissolution 
Dissolution Parameters 
Apparatus USP Apparatus 2 (paddle) 
RPM 50 RPM 
Dissolution medium pH 6.8 Phosphate buffer, 500 mL 
Time 10, 20 and 30 minutes 
Sample collection volume 10 mL 
Temperature 37.0±0.5°C 
Table 12: Dissolution parameters 
6.9 Drug release kinetics:  
        Various models were tested for explaining the kinetics of drug release. To 
investigate the mechanism of drug release rate kinetics from the dosage form, the 
obtained data were fitted with zero-order, first-order, higuchi and korsmeyer - peppas 
release model. 
Zero order release rate kinetics:  
      To investigate zero-order release kinetics, the drug release rate was fitted to the 
equation, 
F = Ko.t 
Where,  
F = drug release, K= release rate constant and t = time taken for drug release. Plot of 
% drug release versus time is linear. (Kenneth A Connors, 1991) 
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First order release rate kinetics:  
       To investigate first-order release kinetics, the drug release rate data was fitted to 
the equation,  
Log (100 – F) = Kt 
A plot of Log % drug release versus time is linear. (Kenneth A Connors, 1991) 
Higuchi release model:  
To investigate Higuchi release kinetics, the release rate data were fitted to the 
following equation.  
F = KH t
1/2
 
Where KH = Higuchi constant.  
In Higuchi model, plot of % drug release verses square root of time is linear. 
(Higuchi W I, 1962) 
 
Korsmeyer – peppas model:  
To investigate Korsmeyer – peppas release kinetics, the release rate data were fitted to 
the following equation,  
Mt/M∞ = K.t
n
 
Where, Mt/M∞ = fraction of drug released.  
K = release constant.  
t= time taken for release.  
n= diffusion exponent.  
If n is equal to 0.89, the release is zero order.  
In this model, a plot of log (Mt/M∞) versus log time is linear. (Koresmeyer et al,. 
1977) 
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7. RESULTS AND DISCUSSION 
7.1 Zolmitriptan Characteristics  
Bulk density    :  0.34 g / mL 
Tapped density   :  0.42 g / mL 
Compressibility index   :  19.05 
Hausner ratio    :  1.24 
Loss on Drying (105°C / Automode) :  3.18% 
PSD by Malvern master Sizer  
     d10 :  6 microns 
     d50 :  11 microns 
               d90 :  16 microns 
Drug Manufacturer   :  Aurobindo Pharma, Hyderabad. 
Batch No    :  ZIP1004110 
7.2 Calibration curve data for Zolmitriptan 
Concentration(µg/ml) Absorbance 
1 0.130±0.003 
2 0.264±0.001 
3 0.385±0.002 
4 0.495±0.001 
5 0.640±0.002 
6 0.758±0.004 
7 0.877±0.001 
8 0.979±0.003 
Table 13. Calibration curve data for Zolmitriptan in 0.1N HCL 
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Standard curve of Zolmitriptan In 0.1N HCL 
 
 
 
 
 
Figure 3: calibration curve of Zolmitriptan in .01N HCL 
  
7.3 FTIR Spectra for Zolmitriptan 
 
Figure 4: FTIR spectra of the Zolmitriptan 
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7.4 FTIR spectra for Zolmitriptan with excipients 
7.4.1 FTIR spectra for Zolmitriptan with citric acid 
 
Figure 5: FTIR spectra for Zolmitriptan with citric acid 
 
7.4.2 FTIR spectra for Zolmitriptan with sucralose 
 
Figure 6: FTIR spectra for Zolmitriptan with sucralose 
 
7.4.3 FTIR spectra for Zolmitriptan with mannitol
 
Figure7: FTIR spectra for Zolmitriptan with mannitol 
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7.4.4 FTIR spectra for Zolmitriptan with sodium Stearyl Fumarate 
 
Figure 8: FTIR spectra for Zolmitriptan with sodium Stearyl Fumarate 
 
7.4.5 FTIR spectra for Zolmitriptan with colloidal silicon dioxide 
 
Figure 9: FTIR spectra for Zolmitriptan with colloidal silicon dioxide 
 
7.4.6 FTIR spectra for Zolmitriptan with ethyl cellulose
 
Figure 10: FTIR spectra for Zolmitriptan with ethyl cellulose 
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7.4.7 FTIR spectra for Zolmitriptan formulation FZ9 
 
Figure 11: FTIR spectra for Zolmitriptan tablets 
7.5 Drug and excipient compatibility studies of optimized formulation  
    The individual IR spectra of Zolmitriptan optimized formulation were shown in the 
figure. The following principle peaks were observed from the IR Spectral analysis. 
   The observed principle peaks were identical in the IR spectra of rug and the IR 
spectra of optimized formulation (FZ9). Hence there was no chemical or physical 
interaction between the drug and the excipient used in this investigation. 
IR spectra of bands 
Table 14. The principle peaks were observed from IR spectra of Zolmitriptan 
S.No Wave Number in cm
-1
 Characteristic bands 
1.  3551.32 O – H stretching 
2.  3402.32 N – H stretching 
3.  2931.47 C – H stretching 
4.  1622.30 C = C stretching 
5.  1455.80 C – H Bending 
6.  1142.94 C – O stretching Ether 
7.  1018.19 C – O stretching 
8.  873.33, 766.75, 669.19, C – H (OOP) For Aromatic rings 
9.  465.97, 450.74, 444.88, C – X stretching 
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   Final blend was characterized with various parameters like bulk density, tapped 
density, angle of repose and loss on drying for each batch and their results were 
tabulated below.  
S. 
No 
Parameters 
FZ1 FZ2 ZF3 FZ4 FZ5 FZ6 FZ7 FZ8 FZ9 
1 
Bulk 
Density(gm/mL) 
0.33 0.35 0.36 0.34 0.38 0.38 0.41 0.39 0.41 
2 Tapped Density 
(gm/mL) 
0.38 0.39 0.4 0.38 0.48 0.48 0.51 0.49 0.50 
3 Angle of Repose 
( °C) 
33 31 31 32 31 31 29 29 28 
4 Loss on Drying 
(%) 
2.93 3.19 3.18 3.14 2.04 2.04 3.12 2.98 2.86 
Table 15; Result for bulk density, tapped density, angle of repose and loss on drying. 
7.6 Particle Size Distribution 
Particle Size Distribution for final blend of the trial batches were performed and the 
results are tabulated below 
S. 
N
o 
Sieve 
size# 
FZ
1 
FZ2 ZF3 FZ4 FZ5 FZ6 FZ7 FZ8 FZ9 
1 20 0 0 0 0 0 0 0 0 0 
2 40 0 2 1 1 1 0 0 0 0 
3 60 5 10 11 12.1 12 7.5 15 15 11.1 
4 80 30 5 6 7.2 5.5 5 5 20 13.9 
5 100 10 5 7.5 9.4 9 17.5 5 17.5 19.4 
6 140 10 43 46 43.8 42 5 20 20 27.8 
7 200 7.5 20 17.5 15.4 17.6 17.5 20 17.5 16.7 
8 Pan 
27.
5 
15 11 11.1 12.9 37.5 35 10 11.1 
Table 16; Particle size distribution results for the final blend  
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7.7 Blend Uniformity 
Percentage content of samples from final blend of trial batches were analyzed and the 
results are tabulated below  
S. No Fz1 Fz2 Fz3 Fz4 Fz5 Fz6 Fz7 Fz8 Fz9 
1 95.7 96.7 94.6 96.6 96.8 98.7 96.7 97.6 98.9 
2 96.9 96.8 95.7 96.8 99.7 98.3 100.6 98.7 99.5 
3 96.9 97.1 95.9 97.2 99.5 98.8 96.7 97.4 99.9 
4 97.1 97.8 96.8 97.5 94.7 99.1 99.8 99.6 99.6 
5 97.3 97.9 97.2 97.9 98.1 99.8 99.6 98.9 99.8 
6 97.5 98.3 97.6 98.1 97.4 98.9 99.3 99.6 99.1 
7 97.9 98.5 97.9 98.5 98.9 99.1 98.1 100.2 98.1 
8 98.3 98.7 98.5 98.7 99.7 99.3 100.9 100.1 99.6 
9 98.5 99.1 98.9 99.2 100.2 99.5 97.9 100 100.8 
10 98.6 99.2 98.9 99.8 97.1 99.6 98.7 99.1 101.2 
AVG 97.47 98.01 97.2 98.03 98.21 99.11 98.83 99.12 99.65 
Min 95.7 96.7 94.6 96.6 94.7 98.3 96.7 97.4 98.1 
Max 98.6 99.2 98.9 99.8 100.2 99.8 100.9 100.2 101.2 
%RSD 0.92 0.93 1.49 1.06 1.76 0.46 1.50 1.00 0.89 
Table 17. Results of Blend uniformity samples of final blend 
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7.8 Tablet Characterization 
7.8.1Weight Variation: 
Weight variation of all the batches were evaluated and the results are tabulated below 
S. No 
FZ1 
(gm) 
FZ2 
(gm) 
FZ3 
(gm) 
FZ4 
(gm) 
FZ5 
(gm) 
FZ6 
(gm) 
FZ7 
(gm) 
FZ8 
(gm) 
FZ9 
(gm) 
1 117.5 121.2 122.3 120.3 121.2 122.6 120.4 120.4 126.0 
2 119.6 120.6 123.0 125.6 123.1 122.4 123.8 126.3 123.1 
3 125.6 122.9 121.6 124.5 123.9 122.4 123.9 121.0 124.8 
4 117.6 126.5 122.3 124.8 121.9 123.6 125.9 123.1 123.9 
5 126.6 125.2 125.6 123.6 124.6 123.1 120.9 124.9 125.1 
6 121.5 124.3 124.3 124.2 122.8 125.2 120.1 124.3 121.4 
7 116.5 121.6 125.3 125.1 123.4 123.7 125.8 126.1 126.0 
8 124.3 124.2 122.8 122.6 124.1 124.9 126.0 125.9 125.8 
9 121.8 120.6 121.5 123.2 123.7 125.1 126.3 123.1 121.9 
10 117.9 121.5 122.9 123.8 122.8 125.0 120.4 124.5 126.1 
Avg 120.9 122.9 123.2 123.8 123.2 123.8 123.4 124.0 124.4 
Min 116.5 120.6 121.5 120.3 121.2 122.4 120.1 120.4 121.4 
Max 126.6 126.5 125.6 125.6 124.6 125.2 126.3 126.3 126.1 
Table 18. Results for weight variation of the formulation  
RESULTS AND DISCUSSION 
 
J.K.K.Nattraja college of pharmacy      Page 81 
 
  
Figure 12; graphical representation of weight variation FZ1 to FZ9 
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7.9.2 Thickness  
Thickness of ten tablets were evaluated from each batch and tabulated in the table 
below 
S. No 
FZ1 
(mm) 
 
FZ2 
(mm) 
 
FZ3 
(mm) 
 
FZ4 
(mm) 
 
FZ5 
(mm) 
 
FZ6 
(mm) 
 
FZ7 
(mm) 
 
FZ8 
(mm) 
 
FZ9 
(mm) 
 
1 2.62 2.85 2.88 2.91 2.82 2.89 2.93 2.93 2.9 
2 2.65 2.86 2.89 2.85 2.82 2.89 2.97 2.93 2.99 
3 2.68 2.81 2.87 2.86 2.91 2.86 2.96 2.94 2.91 
4 2.65 2.83 2.86 2.87 2.91 2.87 2.97 2.97 2.93 
5 2.64 2.85 2.87 2.86 2.91 2.86 2.97 2.94 2.91 
6 2.68 2.86 2.88 2.85 2.83 2.87 2.98 2.93 2.93 
7 2.69 2.87 2.89 2.84 2.82 2.86 2.93 2.98 2.94 
8 2.64 2.85 2.85 2.87 2.83 2.86 2.97 2.96 2.94 
9 2.65 2.83 2.87 2.86 2.83 2.95 2.96 2.97 2.94 
10 2.63 2.87 2.89 2.89 2.9 2.94 2.95 2.97 2.93 
 Avg 2.65 2.85 2.88 2.87 2.86 2.89 2.96 2.95 2.93 
 Min 2.62 2.81 2.85 2.84 2.82 2.86 2.93 2.93 2.90 
 Max 2.69 2.87 2.89 2.91 2.91 2.95 2.98 2.98 2.99 
Table 19.Thickness of tablets of the formulations  
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Figure13; graphical representation of thickness FZ1 to FZ9 
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7.9.3 Hardness: 
Hardness for ten tablets for the trial batches was evaluated and the observation was 
tabulated below.  
S.No FZ1 
(kg/cm
2
) 
FZ2 
(kg/cm
2) 
ZF3 
(kg/cm2) 
FZ4 
(kg/cm2) 
FZ5 
(kg/cm2) 
FZ6 
(kg/cm
2) 
FZ7 
(kg/cm2) 
FZ8 
(kg/cm2) 
FZ9 
(kg/cm2) 
1 3.4 3.4 4.3 4.0 3.1 3.6 4.0 4.1 3.5 
2 3.6 3.5 4.0 4.8 3.8 3.8 4.0 4.5 3.9 
3 3.6 3.6 3.9 4.6 3.7 3.2 3.8 4.4 3.5 
4 3.8 3.5 3.8 4.7 3.6 3.8 3.6 4.6 3.6 
5 3.5 4.3 3.7 4.1 3.9 4.1 3.9 4.1 3.8 
6 4.3 3.7 4.4 4.2 4.1 3.9 4.1 4.3 4.5 
7 3.9 3.8 4.7 4.1 4 4.3 4.8 4.5 4.6 
8 3.5 4.1 4.6 3.6 4.7 4.6 4.3 3.9 4.4 
9 4.1 4.2 4.8 3.9 4.5 4.5 4.9 3.8 4.1 
10 4.1 4.2 3.6 3.6 4.2 4.1 3.9 3.9 4.0 
Avg 
3.8 3.8 4.2 4.2 4.0 4.0 4.1 4.2 4.0 
Min 
3.4 3.4 3.6 3.6 3.1 3.2 3.6 3.8 3.5 
Max 
4.3 4.3 4.8 4.8 4.7 4.6 4.9 4.6 4.6 
Table 20. Hardness of ten tablets and its average for the formulations. 
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Figure 14; graphical representation of hardness FZ1 to FZ9 
7.9.4 Content Uniformity: 
Ten tablets from each batch were analyzed for content uniformity and the results are 
tabulated in percentage is beneath. 
S. No 
FZ1 FZ2 ZF3 FZ4 FZ5 FZ6 FZ7 FZ8 FZ9 
1 98.7 99.9 98.6 99.9 99.7 96.7 98.9 99.6 98.9 
2 102.3 96.6 98.2 101.1 96.5 100.3 98.6 98.4 100.1 
3 103.1 98.7 99.1 98.6 96.9 98.1 98.7 99.8 99.6 
4 99.2 97.8 98.3 97.7 97.9 99.2 97.2 96.4 99.8 
5 99.6 99.9 100.6 98.2 99.1 96.5 99.1 100.1 98.6 
6 104.3 99.5 97.3 98.6 99.3 99.8 99.7 99.8 98.9 
7 100.3 99.1 99.6 100.8 95.8 100 99 99.1 100.1 
8 95.6 99.6 98.3 98.9 99.1 99.9 99.2 99.6 99.9 
9 96.6 99.9 97.9 102.3 99.5 100.8 99.7 100 100.3 
10 100.9 99.3 99.6 99.2 99.7 100.3 99.5 98.9 99.7 
AVG 100.06 99.03 98.75 99.53 98.35 99.16 98.96 99.17 99.59 
Min 95.6 96.6 97.3 97.7 95.8 96.5 97.2 96.4 98.6 
Max 104.3 99.9 100.6 102.3 99.7 100.8 99.7 100.1 100.3 
%RSD 2.74 1.09 0.99 1.47 1.49 1.55 0.74 1.12 0.59 
Table 21;Results of percentage content and %RSD of tablets of formulations 
RESULTS AND DISCUSSION 
 
J.K.K.Nattraja college of pharmacy      Page 87 
 
7.9.5 Friability: 
Initial weight, final weight and percentage weight loss of tablets from each batch for 
checking whether they pass the test for friability. And the results are tabulated below. 
Paramet
ers 
FZ1 FZ2 ZF3 FZ4 FZ5 FZ6 FZ7 FZ8 FZ9 
Initial 
Weight 
(gm) 
6.7504 6.8002 6.7652 6.7786 6.8412 6.7351 6.7638 6.9967 6.8011 
Final 
Weight 
(gm) 
6.6918 6.7804 6.7700 6.7604 6.824 6.7102 6.7449 6.9716 6.7801 
Percenta
ge 
Weight 
loss (%) 
0.87 0.29 -0.07 0.27 0.25 0.37 0.28 0.36 0.31 
Table 22.Friability and its parameters for all the formulations 
7.9.6 Disintegration Time: 
Minimum and maximum time taken by the six tablets from each batch was noted and 
tabulated in the table below 
Table 23. Disintegration time of each formulation 
 
Parameters 
FZ1 FZ2 ZF3 FZ4 FZ5 FZ6 FZ7 FZ8 FZ9 
Minimum 
Time (min) 
0’22 6'00 3'28" 1'45" 0’15 0’18 0’12 0’10 0’11 
Maximum 
Time (min) 
0’29 7'38" 4'45" 2'25" 0’21 0’24 0’16 0’15 0’16 
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7.9.7Assay & Water by Kf 
Results of assay and moisture content evaluated by karlfischer reagent was tabulated 
below  
Parameters 
FZ1 FZ2 ZF3 FZ4 FZ5 FZ6 FZ7 FZ8 FZ9 
Assay(%) 104.2 102.3 101.2 99.6 96.7 101.0 98.7 97.9 99.2 
Water by Kf 
(%) 
5.25 5.15 5.12 5.16 4.22 4.01 4.97 4.96 4.82 
Table 24. Assay and water by kf results of the formulations. 
7.9.8 Related substance 
The analytical method for related substance was performed and the highest unknown 
impurity and total impurity values of the respective batches were tabulated below. 
Parameters 
FZ1 FZ2 ZF3 FZ4 FZ5 FZ6 FZ7 FZ8 FZ9 
Highest Unknown 
Impurity (%) 
0.09 0.77 0.33 0.11 0.23 0.39 0.03 0.02 0.03 
Total Impurities (%) 2.29 2.95 3.00 3.01 3.20 3.19 0.07 0.08 0.06 
Table 25. Highest unknown impurity and total impurities results of the 
respective formulations.  
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7.10 Dissolution 
Percentage release of drug was analyzed during 15 minutes of dissolution and the 
results for the respective batches were tabulated below. 
Formulations 5 min 10 min 15 min 
FZ1 94.3±0.16 98.9±0.78 100.2±0.06 
FZ2 66.8±0.48 85.9±0.95 94.8±0.07 
FZ3 78.8±0.34 88.3±0.66 96.8±0.09 
FZ4 88.0±0.38 94.2±0.57 98.8±0.04 
FZ5 93.2±0.62 99.5±0.12 100.2±0.08 
FZ6 86.5±0.41 96.4±0.18 99.7±0.02 
FZ7 92.7±0.06 99.8±0.06 100.1±0.01 
FZ8 94.8±0.09 100.1±0.12 99.8±0.04 
FZ9 95.8±0.09 99.9±0.02 100.3±0.02 
Table 26. Results of dissolution data of the formulations. 
And the graphical representation of the batches is shown below. 
 
Figure 15: Graphical representation of Percentage dissolution of the 
formulations 
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7.11 Organoleptic evaluation 
The organoleptic evaluation of the tablets was carried out and the observations of the 
respective batches were tabulated below. 
Formulations Organoleptic evaluation 
FZ1 
Average 
FZ2 
Average 
FZ3 
Average 
FZ4 
Average 
FZ5 
Average 
FZ6 
Average 
FZ7 
Good 
FZ8 
Good 
FZ9 
Good 
Table 27; Organoleptic evaluation and its observation. 
7.12 Accelerated stability studies 
30 Tablets with one number of 1mg molecular sieve canister and 1g of oxygen 
absorber canister were used as desiccants along with 6g/yard of nylon coil as dunnage 
is packed in 75cc Heavy Weight HDPE Bottle capped with 33mm Child resistant 
closure having induction seal liner is loaded along with placebo for analytical use in 
each condition. 
Condition                 :            40°C/75% RH- 1st Month 
Description  :  White to off white colored plain flat bevel edged tablets 
Water by Kf (%) :  5.16 
Assay (%)  : 99.7 
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7.12.1 Dissolution 
Percentage drug release of the stability sample (40°C/75% RH- 1st Month) was 
evaluated and their result was tabulated in the table below. 
S.No Time(Min) Percentage Drug Release 
1 5 96.1±0.09 
2 10 99.8±0.04 
3 15 100.1±0.02 
Table 28. Percentage drug release of Stability sample (40°C/75% RH- 1st Month) 
And the graphical representation of the dissolution profile is shown below 
 
Figure 16: Percentage drug release of Stability sample (40°C/75% RH-1st Month) 
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Description  :  White to off white colored plain flat bevel edged tablets 
Water by Kf(%) :  5.46 
0
20
40
60
80
100
120
0 2 4 6 8 10 12 14 16
%
 D
ru
g 
R
el
ea
se
 
Time(Min)  
RESULTS AND DISCUSSION 
 
J.K.K.Nattraja college of pharmacy      Page 92 
 
Assay (%)  : 99.6 
7.12.2 Dissolution 
Percentage drug release of the Stability sample (40°C/75% RH- 3rd Month) was 
evaluated and the results are tabulated. 
S.No Time (Min) %Drug Release 
1 5 97.4±0.07 
2 10 99.8±0.05 
3 15 100.3±0.02 
Table 29. Percentage drug release of Stability sample (40°C/75% RH- 3rd Month) 
And the graphical representation of the dissolution profile is shown below 
 
Figure 17:Percentage drug release of Stability sample (40°C/75% RH-3rd Month) 
Condition: 40°C/75% RH- 6th Month 
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Water by Kf(%)   :          5.61 
Assay (%)    : 99.8 
7.12.3 Dissolution: 
Percentage drug release of the Stability sample (40°C/75% RH- 6th Month) was 
evaluated and the results are tabulated. 
S.No Time(Min) %Drug Release 
1 5 95.2±0.05 
2 10 98.7±0.03 
3 15 99.8±0.02 
Table 30. Percentage drug release of Stability sample (40°C/75% RH- 6th Month) 
And the graphical representation of the dissolution profile is shown below
 
Figure18.Percentage drug release of Stability sample (40°C/75% RH- 6th Month) 
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7.13 Comparison drug release of optimized formulation and marketed 
preparation 
Formulations 5 min 10 min 15 min 
FZ9 95.8±0.06 99.9±0.02 100.3±0.02 
Marketed product 
94.5±0.09 100.1±0.12 99.8±0.04 
Table 31. Comparison drug release of FZ9 and marketed preparation 
 
Figure 19: Comparison drug release of FZ9 and marketed preparation  
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Zolmitriptan was compatible with commonly used excipients, including all excipients 
selected in the final formulation. The stability data generated for the compatibility 
screening is summarized. And the stability changes observed in API were initially 
noted and tabulated below 
Drug  Tests Initial 
Duration / Storage conditions 
2
nd
 week 
55°C 
2
nd
 week 
40°C/75% 
RH 
4
th
 week 
40°C/75% 
RH 
Zolmitriptan 
Assay % 99.5 100.3 100.7 99.1 
TI% 0.053 0.049 0.052 0.066 
Moisture% 0.18 0.43 0.13 0.37 
Table 32. Stability changes in Zolmitriptan on storage in specific condition. 
7.14.1 Compatibility study of drug and co processed excipients 
Compatibility results of active pharmaceutical excipients with co processed 
excipients.  
Zolmitriptan+ 
Excipients 
Tests Initial 
Duration / Storage conditions 
2
nd
 
week 
55°C 
2
nd
 week 
40°C/75% 
RH 
4
th
 week 
40°C/75% 
RH 
Zolmitriptan + 
Pearlitol Flash 
Assay % 98.56 100.02 99.9 98.61 
TI% 0.198 0.173 0.108 0.103 
Moisture% 1.31 1.34 1.29 1.38 
Zolmitriptan + 
Pharma burst 
Assay % 97.99 95.39 97.6 97.55 
TI% 0.199 0.176 0.206 0.256 
Moisture% 0.45 0.67 0.77 0.89 
Zolmitriptan+ 
PanExcea ODT 
Assay % 97.32 99.89 96.13 99.01 
TI% 0.99 0.101 0.118 0.120 
Moisture% 0.31 0.25 0.24 0.33 
Table 33. Compatibility study results with co processed excipients. 
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7.14.2 Compatibility of other diluents 
Other commonly used diluents other than co processed excipients were also analyzed 
for compatibility with API. And the results are tabulated below. 
Zolmitriptan+ 
Excipients 
Tests Initial Duration / Storage conditions 
2
nd
 
week 
55°C 
2
nd
 week 
40°C/75% 
RH 
4
th
 week 
40°C/75% 
RH 
Zolmitriptan+ 
Mannitol 
Assay % 99.98 100.20 97.89 98.99 
TI% 0.063 0.044 0.079 0.082 
Moisture% 1.03 0.89 1.29 1.11 
Zolmitriptan+        
Ethyl cellulose 
Assay % 98.66 98.18 100.42 99.85 
TI% 0.067 0.010 0.091 0.076 
Moisture% 1.01 1.37 1.47 1.69 
Table 34: Compatibility study results with diluents with Zolmitriptan. 
7.14.3 Compatibility with glidants and lubricants 
Compatibility of various glidants and lubricants were analyzed and the results are 
tabulated below 
API + Excipients Tests Initial Duration / Storage conditions 
2
nd
 
week 
55°C 
2
nd
 week 
40°C/75% 
RH 
4
th
 week 
40°C/75% 
RH 
Zolmitriptan 
+Colloidal Silicon 
Di oxide 
Assay % 99.6 99.78 99.89 98.9 
TI% 0.099 0.045 0.067 0.100 
Moisture% 0.69 0.49 0.37 0.89 
Zolmitriptan + 
Sodium Stearyl 
Fumarate 
Assay % 100.53 100.01 99.01 99.97 
TI% 0.070 0.099 0.108 0.99 
Moisture% 0.71 1.00 0.99 1.10 
Table 35: Compatibility of glidants and lubricants with Zolmitriptan 
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7.14.4 Compatibility study of Sweetening agents and flavouring agents 
API + Excipients Tests Initial Duration / Storage conditions 
2
nd
 
week 
55°C 
2
nd
 week 
40°C/75% 
RH 
4
th
 week 
40°C/75% 
RH 
Zolmitriptan API + 
Aspartame 
Assay % 102.0 101.89 99.01 99.56 
TI% 0.099 0.106 0.078 0.136 
Moisture% 2.00 2.36 2.89 2.45 
Zolmitriptan 
+Sucralose 
Assay % 108.02 102.49 106.07 104.61 
TI% 0.080 0.555 0.076 0.949 
Moisture% 0.37 0.69 0.14 0.49 
Zolmitriptan + 
Orange Flavor 
Assay % 97.89 99.01 98.89 99.79 
TI% 0.023 0.067 0.081 0.091 
Moisture% 1.19 1.90 1.79 1.84 
Zolmitriptan 
+Peppermint flavour 
Assay % 99.01 99.76 97.89 96.9 
TI% 0.068 0.089 0.101 0.099 
Moisture% 0.77 0.90 1.07 0.68 
Zolmitriptan +Citric 
Acid 
Assay % 97.89 96.99 97.09 98.00 
TI% 0.099 0.089 0.067 0.023 
Moisture% 1.02 1.08 1.80 1.78 
Table 36; Compatibility of flavour and sweetening agents with Zolmitriptan 
7.15 Comparison of optimized formulation and marketed ODT preparation 
S.No Characteristics Optimized formulation Marketed preparation 
1 Avg weight 125mg 180mg 
2 Hardness 4kg/cm
2
 4.7kg/cm
2
 
3 Thickness 2.93mm 3.6mm 
4 Friability 0.31% 0.85% 
5 Disintegration time 0’11 0’18 
6 Dissolution 100.3% 99.1% 
7 Weight variation 99.52% 100.5% 
8 Mouth feel Compare to better Good 
9 Assay (Avg) 99.6% 99% 
Table 37; Comparison of optimized formulation and marketed ODT preparation 
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7.18 Drug release kinetics studies 
7.18.1 Zero order release kinetics 
 
 
Figure 20; zero order release kinetic studies 
7.18.2 First order release kinetics  
 
 
Figure 21; first order release kinetic studies 
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7.18.3 Higuchi release kinetics 
 
Figure 22; Higuchi release kinetics 
 
7.18.4 Hixon-crowell cubic root kinetics 
 
 
Figure 23; Hixon-crowell cubic root kinetics 
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7.18.5 Korse meyer peppas kinetics 
 
Figure 24; Korse meyer peppas kinetics 
 
Table 38: Regression values of in-vitro release kinetic study optimized 
Zolmitriptan immediate release Tablet (FZ9) 
On the basis of highest f2 and lowest f1 value, the formulation FZ9 was chosen or drug 
release kinetic and mechanism of release studies. The in vitro dissolution data of 
Zolmitriptan immediate release tablets (FZ9) were fitted in different kinetic models 
viz. zero order, first order, Higuchi, Hixson-Crowell and Korse Meyer- Peppas 
equation; and the graphs were plotted figure. The Korse Mayer Peppa’s kinetic plots 
Regression values(R
2
) FZ9 
Zero order release kinetics 0.993 
First order release kinetics 0.922 
Hixon-crowell cubic root kinetics 0.954 
Higuchi release kinetics 0.717 
Korse meyer peppas kinetics 0.991 
RESULTS AND DISCUSSION 
 
J.K.K.Nattraja college of pharmacy      Page 101 
 
were found to be fairly linear as indicated by their highest regression values (0.991) 
for FZ9 formulation. The release exponent ‘n’ for optimized formulation FZ9 was 
found to be 0.991  (0.5 < n < 1), that appears to indicate a coupling of the diffusion 
and erosion mechanism so-called anomalous diffusion. So in present study in vitro 
drug release kinetic of Zolmitriptan immediate release tablet followed Peppas release 
kinetic model and the drug release mechanism was said to be anomalous diffusion 
coupled with erosion. The regression values of all the release kinetics were presented 
in the table 38. 
DISCUSSION 
Zolmitriptan fast dissolving tablets were prepared by direct compression method 
using superdisintegrants is Pharmaburst ODT, in varying concentrations. 
 
Angle of repose: is 28° shows good flow.  
 
Bulk density and tapped density: is 0.410(g/ml) and 0.500 (g/ml), respectively. The 
values for compressibility index and Hausner ratio is 19.05 and 1.24, respectively. 
The results for pre-compressed parameters are shown in Table 15. 
 
Weight variation test is found 121.4 mg to 126.1 mg as per IP specification. 
Friability: Less than 0.31%, the results indicate that the percentage losses were not 
more than 1.0% (complies IP specifications). Thickness: Range from 2.90 mm to 2.99 
mm; the results indicate that the tablets are suitable for packing. 
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Content uniformity was found in between 98.62% and 100.3%. Hardness of the 
tablet was found to be between 4 to 4.6 kg/cm
2
. The results indicate that the tablets 
are mechanically strong and are in limit.  
 
Disintegration time which was in-between 0’11 sec to 0’16 sec, the results indicate 
that disintegration time of tablets is within 30 seconds.  
 
Dissolution study was carried out in 6.8 pH phosphate buffer for formulations FZ1, 
FZ2, FZ3, ZF4, FZ5, ZF6, FZ7, FZ8, and FZ9 from time 0 to 15 min, the results are 
shown in Table 26. And % assay for optimized batch was found to be 99.2 % as 
shown in Table 24 
Comparative dissolution study was carried out in 6.8 pH phosphate buffer for 
formulations FZ9 and marketed product. The results are shown in table 31 and figure 
19. 
 
Storage condition: Tablets were stored at 45°C ± 2°C/75% for a storage period of 0, 
30, 60, and 90 days, Hardness was increased with time but in all cases, hardness was 
within the limit. Disintegration time: At various storage conditions increases but 
maximum 20 sec which is < 30 seconds (specification of IP). Dissolution studies 
shows there was no significant change in dissolution data of formulations at initial 
and after specified storage period. 
CONCLUSION 
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8. CONCLUSION 
Orodispersible tablets of Zolmitriptan are prepared by direct compression 
method. The formulation FZ9 containing 10% of superdisintegrant (i.e) 
Pharmaburst ODT has shown best release with 100.3% at the end of 15minuts. 
The effervescent mixture further assists in taste masking of Zolmitriptan. 
According to FTIR studies there is no incompatibility shown in FZ9. The 
formulation FZ9 was stable at 40°C±2ºC and 75%RH±5%RH. 
In conclusion formulation FZ9 achieved the targets of the present study such as, 
 Not require water to swallow, but it should dissolve or 
disintegrate in the mouth in matter of seconds. 
 
 To mask the bitter taste. 
 
 Have a pleasant mouth feel. 
 
 Rapid dissolution of drug and absorption which may 
produce rapid, onset of action. 
 
 Improved bioavailability. 
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